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Abstract 
Nanomaterials offer new opportunities for cancer diagnosis and treatment. Multifunctional 
nanoparticles harboring various functions including targeting, imaging, therapy, and etc have 
been intensively studied aiming to overcome limitations associated with conventional cancer 
diagnosis and therapy. Of various nanoparticles, magnetic iron oxide nanoparticles with su-
perparamagnetic property have shown potential as multifunctional nanoparticles for clinical 
translation because they have been used asmagnetic resonance imaging (MRI) constrast agents 
in clinic and their features could be easily tailored by including targeting moieties, fluorescence 
dyes, or therapeutic agents. This review summarizes targeting strategies for construction of 
multifunctional nanoparticles including magnetic nanoparticles-based theranostic systems, and 
the various surface engineering strategies of nanoparticles for in vivo applications. 
Key words: Multifunctional nanoparticles, magnetic nanoparticles, targeting ligand, bioconjuga-
tion, surface engineering, long circulation 
Introduction 
Cancer remains one of the most deadly diseases 
in the world, and the number of new cases increases 
each  year  [1].  Despite  rapid  advances  in  diagnostic 
procedures and treatments, the overall survival rate 
from cancer has not improved substantially over the 
past 30 years [2]. There is a need, therefore, to develop 
novel  approaches  for  the  accurate  detection  of  ear-
ly-stage of cancer and for targeted therapies based on 
the cancer-specific markers, which could lead to per-
sonalized medicine. Recent advances in nanomateri-
als have explored passive and active targeting strate-
gies for enhancing intratumoral drug concentrations 
while limiting the unwanted toxicity to healthy tissue 
[3-5].  The  targeted  delivery  of  nanomaterials  can 
overcome  difficulties  associated  with  conventional 
free  anticancer  drugs,  including  insolubility  under 
aqueous  conditions,  rapid  clearance,  and  a  lack  of 
selectivity,  resulting  in  nonspecific  toxicity  toward 
normal cells and lower the dose of drugs delivered to 
the  cancer  cells  [6].  Inorganic  nanomaterials  with  a 
variety  of  unique  intrinsic  physical  properties  have 
attracted growing interest for use in biomedical im-
aging  applications  [7,8].  Among  the  imaging  nano-
probes, magnetic iron oxide nanoparticles have been 
widely used as MRI contrast agents for cancer imag-
ing,  helping  to  provide  anatomical  details  and  fur-
thermore real-time monitoring of the therapeutic re-
sponse [9,10]. In this review, we first discuss selective 
targeting strategies using nanoparticles for achieving 
effective cancer detection and treatment; secondly, we 
discuss the various targeting moieties used as ‘escort’ 
molecules to specific tumor tissues; third, we discuss 
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methods  of  conjugating  the  functional  moieties  to 
nanoparticles; finally, we discuss strategies for opti-
mizing the nanoparticle surfaces for in vivo applica-
tions. We highlight the potential utility of magnetic 
nanoparticle-based  theranostic  systems,  which  thus 
far are shown to be suitable for clinical use. 
Passive and active targeting 
Most nanoparticles are expected to accumulate 
in tumors due to the pathophysiologic characteristics 
of  tumor  blood  vessels.  Delivery  of  nutrients  to  an 
actively growing tumor with a volume greater than 2 
mm3 becomes diffusion-limited, and new blood vessel 
formation is required to supply nutrients and oxygen 
[11].  The  incomplete  tumor  vasculature  results  in 
leaky vessels with enlarged gap junctions of 100 nm to 
2 μm, depending on the tumor type, and macromol-
ecules  easily  access  the  tumor  interstitium  [12-14]. 
Tumors also have a compound retention time higher 
than  that  of  normal  tissues  because  tumors  lack  a 
well-defined lymphatic system [15,16]. These features 
provide  an  enhanced  permeability  and  retention 
(EPR) effect, which constitutes an important mecha-
nism for the passive targeting and selective accumu-
lation of nanoparticles in the tumor interstitium. Dox-
il®,  a  poly(ethylene  glycol)-coated  (PEGylated)  lipo-
somal  system  for  doxorubicin  (Dox)  delivery,  and 
Abraxane®,  albumin-bound  paclitaxel  nanoparticles 
for the treatment of metastatic breast cancer, are rep-
resentative  examples  of  US  food  and  Drug  Admin-
istration (FDA)-approved nanocarrier-based drugs for 
cancer  therapy.  These  agents  circulate  in  the  body 
with a half-life about 100 times longer than that of free 
anticancer drugs while simultaneously reducing sys-
temic toxicity [17-21].  
However,  passive  targeting  approaches  suffer 
from several limitations. Targeting cancer cells using 
the EPR effect is not feasible in all tumors because the 
degree of tumor vascularization and porosity of tu-
mor vessels can vary with the tumor type and status 
[12,22]. In addition, cancer cells can display a reduced 
number of specific interactions that lead to internali-
zation of nanoparticles. In addition to preventing in-
teractions  between  nanoparticles  and  opsonins, 
PEGylated  surfaces  can  also  reduce  interactions  be-
tween nanoparticles and cell surfaces [23-26]. The lack 
of  control  can  lead  to  drug  expulsion  and  induce 
cancer cells to develop resistance toward a variety of 
drugs (multiple drug resistance, MDR), which inevi-
tably  reduces  any  therapeutic  effects  [27].  One  ap-
proach  to  overcoming  these  limitations  is  to  attach 
targeting  moieties  to  the  nanoparticle  surfaces.  Na-
noparticles that present targeting moieties can bind to 
target cells through ligand-receptor interactions that 
induce  receptor-mediated  endocytosis  and  drug  re-
lease inside the cell. Efficient binding and internaliza-
tion requires that receptors are expressed exclusively 
on target cancer cells (104–105 copies per cell) relative 
to  normal  cells,  and  expression  should  be  homoge-
nous across all targeted cells [28]. This delivery strat-
egy achieves a high targeting specificity and delivery 
efficiency, while avoiding nonspecific binding and the 
MDR efflux mechanism [29]. At present, several tar-
geted delivery systems are under clinical trials, such 
as  transferrin  receptor  targeted  cytotoxic  plati-
num-based  oxaliplatin  in  a  liposome  (MBP-426), 
transferrin receptor targeted cyclodextrin-containing 
nanoparticles  with  siRNA  payload  (CALAA-01),  or 
prostate-specific membrane antigen (PSMA) targeted 
polymeric  nanoparticles  containing  docetaxel 
(BIND-014). Table 1 lists the nanoparticle-based drugs 
that  are  approved  or  under  clinical  development. 
Although  ligand-mediated  targeting  technologies 
have not yet made a considerable clinical impact on 
human health, it will soon be feasible to develop tar-
geted nanoparticle candidates for clinical translation 
[30]. 
Multifunctional nanoparticles for targeted im-
aging and therapy 
The multifunctional properties of nanoparticles 
convey unique advantages for the cancer-specific de-
livery of imaging and therapeutic agents [42]. Several 
ligands  with  therapeutic,  diagnostic,  or  barri-
er-avoiding properties can be incorporated across the 
large nanoparticle surface area in a single nanoparti-
cle  system.  Multivalent  targeting  significantly  in-
creases the binding affinity of a particle toward a tar-
get cell [43]. Magnetic iron oxide nanoparticles have 
been  shown  to  be  suitable  for  use  as  theranostic 
agents by employing their intrinsic diagnostic capa-
bilities  in  the  context  of  MRI  applications.  Surface 
modifications may be easily introduced through con-
jugation  with  targeting  moieties  (e.g.,  antibodies, 
peptides, small molecules, or aptamers), fluorescence 
dyes,  genes,  or  drugs  to  provide  multimodal  func-
tionalities [44-47]. In the following section, multifunc-
tional nanoparticle systems that feature a variety of 
targeting  moieties for  in vitro and/or  in vivo cancer 
imaging and therapy, including magnetic nanoparti-
cles, will be discussed. 
 
2. Types of targeting moieties 
Targeting  moieties  are  classified  as  proteins 
(mainly  antibodies  and  their  fragments),  peptides, 
nucleic acids (aptamers), small  molecules,  or others 
(vitamins  or  carbohydrates).  Although  monoclonal Theranostics 2012, 2(1) 
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antibodies (mAbs) have been widely used as escort 
molecules for the targeted delivery of nanoparticles, 
several limitations including large size and difficulty 
in conjugation to nanoparticles have hampered their 
uses.  Thus,  other  smaller-sized  ligands  including 
peptides have attracted greater attention these days. 
This section will discuss the types of targeting moie-
ties that may be used for decorating multifunctional 
nanoparticles, as well as their potential benefits and 
drawbacks. 
 
Table 1. Nanoparticle-based drugs that have been approved or are being tested in the clinic. 
 
 
 
Antibody-based targeting  
Targeted ligand development over the past sev-
eral decades has focused on antibodies as a class. The 
presence of two epitope binding sites in a single mol-
ecule offers an exceedingly high selectivity and bind-
ing  affinity  for  the  target  of  interest.  Rituximab 
(Rituxan®)  for  non-Hodgkin’s  lymphoma  treatment 
[48],  Trastuzumab  (Herceptin®)  for  breast  cancer 
treatment [49], Bevacizumab (Avastin®) designed to 
inhibit  angiogenesis  [50],  and  Cetuximab  (Erbitux®) 
for  advanced  colorectal  cancer  treatment  [51]  have 
been  developed  and  approved  by  FDA  for  use  as 
therapeutic antibodies. However, these are large, ex-
pensive to manufacture, and there is some degree of 
variation from batch to batch. Antibodies can poten-
tially induce an immunogenic response. To mitigate 
such a response, recent developments in the field of 
antibody  engineering  have  yielded  humanized,  chi-
meric, or fragmented antibodies. 
Hadjipanayis et al. employed an anti-epidermal 
growth factor receptor (EGFR) deletion mutant anti-
body to fabricate iron oxide nanoparticles for targeted 
imaging  and  therapeutic  treatment  of  glioblastoma 
[52]. The EGFR variant III (EGFRvIII) deletion mutant 
is specifically expressed in malignant glioma cells but 
not in normal brain tissue. Selective binding to this 
mutant  EGFR  protein  was  achieved  by  creating  a 
polyclonal  rabbit  antibody  toward  the  chemically 
synthesized  14-amino-acid  fusion  junction  sequence 
(EGFRvIIIAb).  Covalent  conjugation  of  the  purified 
rabbit  polyclonal  EGFRvIIIAb  to  the  amphiphilic 
triblock  copolymer-coated  iron  oxide  nanoparticles 
[53]  yielded  a  stable  glioblastoma-targeting 
theranostic  agent  (EGFRvIIIAb-IONPs)  (Figure  1A). 
The EGFRvIIIAb-IONPs were effectively delivered to 
the intratumoral and peritumoral regions in the brain 
using convection enhanced delivery (CED), which is a 
continuous method of injection under a pressure gra-
dient formed by the fluid containing the therapeutic 
agent  [54].  Generally,  CED  prevents  nanoparticles 
from becoming trapped in the liver, spleen, or circu-Theranostics 2012, 2(1) 
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lating macrophages after intravenous administration, 
and  it  helps  in  bypassing  the  blood-brain  barrier 
(BBB). CED is, therefore, increasingly used to distrib-
ute therapeutic agents for the treatment of malignant 
gliomas [55-57]. Athymic nude mice implanted with a 
human  U87∆EGFRvIII  glioma  model  tumor  under-
went CED of EGFRvIII-IONPs to test the accuracy of 
MRI  monitoring  and  the  efficacy  of  the  antitumor 
effects. The T2-weighted MRI signal at the tumor site 
decreased after CED of EGFRvIII-IONPs, and the total 
area in which a signal drop was observed was larger 7 
days after CED, showing that the nanoparticles had 
dispersed. A significant increase in survival was ob-
served  in  animals  that  underwent  CED  with  EG-
FRvIIIAb or EGFRvIIIAb-IONPs as a result of the in-
hibition of EGFR phosphorylation, whereas CED with 
the untreated control or IONPs did not result in an 
increase  in  the  survival  rate  (Figures  1B–1F).  These 
results  indicated  that  the  MRI-guided  CED  of  EG-
FRvIIIAb-IONPs resulted in specific targeting of the 
devastating brain tumors. 
Wei  and  Gao  et  al.  used  a  single  chain  an-
ti-prostate stem cell antigen (PSCA) antibody (scAbP-
SCA) as a specific ‘address tag’ for prostate cancer tar-
geted  imaging  and  therapy  [58].  Prostate  stem  cell 
antigen is a prostate-specific glycosyl phosphatidyl-
inositol-anchored glycoprotein that is marginally ex-
pressed  in  normal  prostate  and  overexpressed  in 
prostate cancer tissues [59]. As shown in Figure 2A, 
the scAbPSCA was prepared by cleaving intact AbPSCA 
with mercaptoethylamine (MEA), followed by linking 
to  maleimide-PEG-carboxyl  (MAL-PEG-COOH)  and 
covalent  conjugation  to  multifunctional  polymeric 
vesicles that had been formed by the entrapping of 
superparamagnetic  iron  oxide  (SPIO)  nanoparticles 
and  docetaxel  (Dtxl)  by  amine-terminated 
poly(lactic-co-glycolic)  acid.  The  scAbP-
SCA-Dtxl/SPIO-NPs  were  147  nm  in  size,  as  deter-
mined  by  dynamic  light  scattering  (DLS),  and  the 
amounts  of  SPIOs  and  Dtxl  in  the  polymer  matrix 
were  23  wt%  and  6.02  wt%,  respectively.  The  high 
drug encapsulation efficiency was due to partitioning 
of Dtxl into the oleic acid and oleylamine shell of the 
SPIOs, which acted as a drug reservoir, thereby ex-
hibiting a triphasic drug release pattern rather than 
the  common  two-phase  kinetic  release  pattern,  in-
cluding burst effects of an initial release stage, as ob-
served in vesicles without SPIOs. An in vitro cytotoxi-
city study demonstrated the antiproliferative effects 
of the multifunctional vesicles toward prostate cancer 
cells.  As  indicated  in  Figures  2B  and  2C,  PC3  cells 
incubated  with  scAbPSCA-Dtxl/SPIO-NPs  produced 
distinct  darkened  regions  in  the  T2-weighted  MRI 
compared to the polymeric vesicles without scAbPSCA 
or  Endorem®  (a  commercial  contrast,  Guerbet, 
France).  This  result  demonstrated  that  the  scAbP-
SCA-Dtxl/SPIO-NPs  could  be  used  as  MRI  contrast 
agents  for  prostate-targeted  imaging  and  real-time 
monitoring of therapeutic effects.  
 
 
 
Figure  1.  (A)  Schematic  diagram  showing  EGFRvIII-IONPs.  (B-F)  Survival  studies  of  nude  mice  implanted  with  the 
U87ΔEGFRvIII glioma model. (B) T2-weighted MRI showing a tumor region with a bright signal 7 days after tumor im-
plantation (arrow). (C) A tumor is shown (arrow) after injection of a gadolinium contrast agent (Gd-DTPA). (D) The MRI 
signal decreased (arrow) after CED of EGFRvIIIAb-IONPs. (E) EGFRvIIIAb-IONP dispersion and T2 signal decrease (arrow) 
4 days after CED. (F) Survival curve of the nude mice bearing U87ΔEGFRvIII cells after a treatment regimen of MRI-guided 
CED: the untreated control, IONPs, EGFRvIIIAb, or EGFRvIIIAb-IONPs. Reproduced with permission from ref. [52]. 
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Figure 2. (A) Schematic diagram showing the formulation of scAbPSCA-Dtxl/SPIO-NPs. T2-weighted imaging (B) and the MR 
signal  intensity  (C)  of  PC3  cells  (1×10
6)  after  2  h  incubation  with  (a)  scAbPSCA-Dtxl/SPIO-NPs,  (b) 
PEG-PLGA-Dtxl/SPIO-NPs, or (c) Endorem
® with 1.5 T MRI scanning. Reproduced with permission from ref. [58]. 
 
In a similar manner, Chen and Shuai et al. used 
scAb as a targeting molecule. They designed a CD3 
single  chain  antibody  (scAbCD3)  functionalized 
nonviral polymeric vector for gene delivery to T cells 
[60]. This polymeric vector was first complexed with 
superparamagnetic  iron  oxide  nanoparticles  (SPI-
ONs), then was used to condense a therapeutic gene 
plasmid as a dual-purpose probe (T lymphocyte tar-
geted gene delivery and MRI contrast agent). In ma-
ture T cells, engagement of T cell antigen receptors, 
such as the CD3 receptor, can lead to the initiation of 
anergy,  and  such  receptors  can  potentially  mediate 
targeted  gene  delivery  to  T  cells.  Thus,  the 
scAbCD3-conjugated,  poly(ethylene  glycol)-grafted 
polyethyleneimine  (PEG-g-PEI)-coated  SPIONs 
(scAbCD3-PEG-g-PEI-SPION)  were  synthesized  by 
bioconjugation  and  ligand  exchange  methods  [61]. 
The  targeting  polyplexes  (scAbCD3-PEG-g-PEI- 
SPION/DNA) were then prepared by incorporating a 
diacylglycerol kinase (DGKα) gene that could impair 
T  cell  receptor  (TCR)  signaling  and,  consequently, 
resulted  in  the  anergy  of  T  cells  [62,63].  The 
scAbCD3-immobilized  polyplexes  were  efficiently 
taken up by the target T cells (HB8521) via CD3 re-
ceptor-mediated  endocytosis,  as  indicated  by  the 
T2-weighted MRI. Interestingly, although gene trans-
fection  of  T  cells  is  generally  difficult,  quantitative 
flow  cytometric  analysis  indicated  that  the  gene 
transfection efficiency of the targeted polyplexes was 
high  (81.95%)  compared  to  the  efficiency  of  poly-
plexes  without  scAbCD3  functionalization  (7.39%). 
Additionally, after DGKα genes were transferred into 
HB8521  cells,  lower  levels  of  cell  proliferation  and 
IL-2 expression were observed in response to immune 
stimulation  in  cells  transfected  with  the  targeted 
polyplexes  than  in  cells  that  hadn’t  been 
pre-transfected  during  stimulation,  demonstrating 
that MRI-visible targeted nanoparticles can dampen 
TCR-induced diacylglycerol signaling. 
Immunoliposomes  (antibody-directed  lipo-
somes) are common pharmaceutical carriers for tar-
geted drug delivery because of their unique ability to 
encapsulate both hydrophilic and hydrophobic ther-
apeutic agents and due to their simple preparation. 
Wu et al. developed in vivo lung cancer targeted im-
munoliposomes  using  an  anti-c-Met  antibody  [64]. Theranostics 2012, 2(1) 
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The  receptor  for  hepatocyte  growth  factor  (HGF), 
c-Met, is abundantly expressed in 25% of non-small 
cell lung cancer patients, and activation of this protein 
is reported to trigger cancer cell proliferation, migra-
tion, and invasion [65, 66]. Wu et al. prepared indi-
vidual  targeted  therapeutic  vehicles  and  imaging 
probes.  First,  an  anti-c-Met  single  chain  variable 
fragment  (scFv)  antibody  was  identified  by  phage 
display (Ms20, Kd value; 9.14 nM), and cysteine resi-
dues were fused for site-direct conjugation with ma-
leimide-modified  PEG-terminated  liposomal  Dox. 
The  resulting  Ms20-conjugated  liposomal  Dox 
(Ms20-LD)  was  used  as  a  therapeutic  vehicle.  Inor-
ganic quantum dots (QD) were also utilized to pre-
pare  targeted  diagnostic  tools  (Ms20-QD).  Because 
c-Met expression appeared in angiogenic endotheli-
um as well as in tumor cells [67], the dual targeting 
properties, including inhibition of tumor growth and 
prevention  of  angiogenesis,  were  observed  in  an 
Ms20-LD-injected  H460-bearing  SCID  mouse  xeno-
graft model. In addition, Ms20-LD improved chemo-
therapeutic  drug  delivery  by  inhibiting 
c-Met-transient  or  c-Met-constitutive  activation  of 
cancer  cells.  An  in  vivo  tumor  homing  study  of 
Ms20-QD  supported  that  Ms20  provided  selective 
delivery to solid tumors and was potentially useful as 
a lung tumor targeted theranostic agent. 
Peptide-based targeting 
Peptides are attractive targeting molecules due 
to their small size, low immunogenicity, and ease of 
manufacture  at  small  costs  [68].  Peptide-based  tar-
geting ligands may be identified via several methods. 
Most commonly, they are obtained from the binding 
regions of a protein of interest. Phage display tech-
niques can also be used to identify peptide-targeting 
ligands.  In  a  phage  display  screen,  bacteriophages 
present a variety of targeting peptide sequences in a 
phage display library (~1011 different sequences), and 
target peptides are selected using a binding assay [69]. 
Cilengitide,  a  cyclic  peptide  with  integrin  binding 
affinity, is currently in phase II clinical trials for the 
treatment of non-small cell lung cancer and pancreatic 
cancer  [70].  In  2006,  an  Adnectin  for  human  VEGF 
receptor 2 (Angiocept), a 40 amino acid thermostable 
and  protease-stable  oligopeptide,  entered  phase  I 
clinical trials for the treatment of advanced solid tu-
mors and non-Hodgkin’s lymphoma. Although pep-
tides can have drawbacks, such as a low target affinity 
and susceptibility to proteolytic cleavage, these issues 
may be ameliorated by displaying the peptides mul-
tivalently  or  by  synthesizing  them  using  D-amino 
acids. Recently, peptides have been used to fabricate 
multifunctional nanoparticles for targeted cancer im-
aging and therapy. 
Medarova  et  al.  synthesized  a  breast  tu-
mor-targeted nanodrug designed to specifically shut-
tle siRNA to human breast cancer while simultane-
ously allowing for the noninvasive monitoring of the 
siRNA delivery process [71]. The nanodrug consisted 
of  SPIONs  for  MRI  monitoring,  Cy5.5  fluorescence 
dye for near-infrared (IR) optical imaging, and siRNA 
to target the tumor-specific antiapoptotic gene BIRC5. 
Magnetic  iron  oxide  nanoparticles  are  extensively 
used as multimodal imaging probes in combination 
with optical fluorescence dyes to obtain the benefits of 
optical  imaging,  such  as  rapid  screening  and  high 
sensitivity. Because tumor-associated underglycosyl-
ated mucin-1 (uMUC-1) antigen is overexpressed in 
>90% of breast cancers and in >50% of all cancers in 
humans [72], researchers have decorated nanodrugs 
with uMUC-1-targeting EPPT synthetic peptides for 
selective  tumor  targeting.  As  shown  in  Figure  3A, 
amine-functionalized  superparamagnetic  iron  oxide 
nanoparticles  with  a  cross-linked  dextran  coating 
(MN) have been prepared, and a Cy5.5 dye was con-
jugated  to  the  surface  of  nanoparticles  to  produce 
MN-Cy5.5.  Subsequently,  thiol-modified, 
FITC-labeled EPPT peptides and siRNA were coupled 
to  MN-Cy5.5  via  a  heterofunctional  cross-linker, 
N-succinimidyl  3-(2-pyridyldithio)  propionate 
(SPDP).  The  resulting  therapeutic  and  diagnostic 
nanodrug  (MN-EPPT-siBIRC5)  exhibited  superpara-
magnetic and fluorescence properties. After intrave-
nous injection of the nanodrugs into mice with BT-20 
breast  tumors,  the  tumors  were  clearly  imaged,  as 
verified simultaneously by T2 MRI and near-IR opti-
cal  imaging  (Figure  3B).  Systemic  administration  of 
the nanodrug once a week over 2 weeks induced con-
siderable levels of necrosis and apoptosis in the tu-
mors as a result of the siBIRC5-mediated inhibition of 
the antiapoptotic survivin protooncogene, translating 
into a significant decrease in tumor growth rate (Fig-
ure  3C).  This  tumor-targeted,  imaging-capable 
nanodrug  highlights  the  potential  of  MRI-guided 
tumor  treatment,  which  can  be  used  to  quantify 
changes  in  the  tumor  volume  over  the  treatment 
schedule as well as to guide selection of an optimal 
treatment time course. 
Treatment of malignant brain tumors is one of 
the most formidable challenges in oncology due to the 
difficulties associated with drug delivery across the 
BBB to the tumor. Zhang et al. developed an in vivo 
brain  tumor  targeting  magnetic/optical  nanoprobe 
capable of selectively accumulating in brain tumors 
across the BBB via chlorotoxin (CTX) [73]. CTX is a 
36-amino  acid  peptide  that  functions  well  as  a  tu-
mor-targeting ligand due to its permeation across an Theranostics 2012, 2(1) 
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intact BBB as well as its strong affinity for tumors of 
neuroectodermal  origin  [74].  The  nanoprobe  com-
prised  an  iron  oxide  nanoparticle  coated  with  a 
PEGylated chitosan-branched copolymer (NPCP) that 
included  exposed  amine  groups,  to  which 
N-succinimidyl-S-acetylthioacetate  (SATA)-function-
alized  CTX  and  the  near-IR  dye  Cy5.5  were  conju-
gated  via  iodoacetate  and  amide  linkages,  respec-
tively (Figure 4A). In vivo MRI contrast enhancement 
and optical imaging were then evaluated in a trans-
genic mouse model, ND2:SmoA1 that closely resem-
bles  human  medulloblastoma  [75],  which  arises 
spontaneously in the cerebellum [76] and maintains 
an intact BBB [77]. After administration of the targeted 
NPCP-CTX  via  tail  vein  injection,  a  significant  in-
crease  in  the  MRI-derived  R2  values  (s–1)  was  ob-
served  at  the  periphery  of  the  cerebellum  (tu-
mor-containing tissue) in ND2:SmoA1 mice, whereas 
images of the frontal lobe region (healthy tissue) of 
these mice or nontargeting NPCP injected mice did 
not  show  apparent  R2  shifts  between  pre-injection 
and  post-injection  (Figure  4B).  Additionally, 
wild-type  mice  (bearing  no  tumors)  injected  with 
these nanoprobes showed no considerable accumula-
tion  in  the  brain  (Figure  4C),  implying  the  specific 
accumulation of nanoprobes in the tumor after cross-
ing  the  BBB  with  minimal  accumulation  in  normal 
tissues.  Near-IR  optical  imaging  also  confirmed  the 
preferential  accumulation  of  NPCP-Cy5.5-CTX  only 
in  brain  tumor  regions  at  both  2  h  and  120  h 
post-injection  (Figure  4D  and  4E).  This  nanoprobe 
platform may be tailored and further developed to-
ward brain tumor targeted therapeutic  nanoparticle 
systems. 
 
 
Figure 3. (A) Schematic diagram showing the synthesis of MN-EPPT-siBIRC5. (B) Representative pre-contrast images and 
24 h post-contrast T2-weighted images (top), and color-coded T2 maps (bottom) of the tumor-bearing mice intravenously 
injected with MN-EPPT-siBIRC5 (10 mg/kg Fe). (C) Relative tumor volume measurements of MN-EPPT-siBIRC5- and 
MN-EPPT-siSCR-injected animals over the course of treatment. Reproduced with permission from ref. [71]. Theranostics 2012, 2(1) 
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Figure 4. (A) Schematic diagram of the NPCP-Cy5.5-CTX nanoprobes. In vivo MR images of ND2:SmoA1 (B) and wild-type 
mice (C) acquired before and 48 h after administration of either NPCP-CTX or the NPCP nanoprobes. Colorized R2 maps 
of the brain region were superimposed onto the proton density-weighted images. (D-E) In vivo near-IR fluorescence images 
of autochthonous medulloblastoma tumors in ND2:SmoA1 mice injected with NPCP-Cy5.5-CTX or NPCP-Cy5.5, along-
side those receiving no injection: 2 h post-injection (D) and 120 h post-injection (E). Ex vivo fluorescence images of mice 
brains from the same mice following necropsy (inset). The spectral gradient bar corresponds to the fluorescence intensity 
(p/s/cm
2/sr) in the images. Reproduced with permission from ref. [73]. 
 
An acidic extracellular tumor microenvironment 
(pH 5.8–7.1) provides another strategy for increasing 
tumor selectivity. A hypoxic metabolic state creates 
acidic conditions around a tumor, which can provide 
a triggering signal for the cancer-targeted drug deliv-
ery  of  nanoparticles  [78-80].  Using  this  strategy, 
Zhang et al. designed a glioma targeting pH-sensitive 
siRNA  nanovector  using  CTX  [81].  The  nanovector 
was composed of an iron oxide magnetic nanoparticle 
core  coated  with  three  different  types  of  functional 
molecule: the primary amine group-blocked polyeth-
yleneimine  (PEI)  as  a  pH-sensitive  coating  layer, 
siRNA as a therapeutic payload, and CTX as a tumor 
targeting ligand. As an amine blocker  of PEI, citra-
conic anhydride (2-methylmaleic anhydride) reacted 
with  the  primary  amine  group  of  PEI  to  provide  a 
terminal carboxylate, which could be hydrolyzed only 
under acidic conditions. This reversible charge con-
version from positive to negative under acidic condi-
tions in a pH-sensitive manner may reduce the cyto-
toxicity of PEI and minimize nonspecific cellular up-
take at physiological pH conditions [78,82]. To syn-
thesize  the  nanovector,  amine-functionalized  iron 
oxide nanoparticles (NPs) were prepared by coating 
with  amine-terminated  PEG.  The  primary  amine 
groups on the NPs were reacted with Traut’s reagent 
to provide thiol-modified NPs. The amine groups in 
PEI  that  remained  after  the  citraconylation  reaction 
were then activated with SPDP for conjugation onto 
the NPs. The resultant pH-sensitive PEI-coated NPs 
exhibited negligible cytotoxicity at pH 7.4 as a result 
of the surface-exposed carboxylates on NPs, however, 
the surface charge on the NPs increased under acidic 
conditions  due  to  both  deblocking  of  the  primary 
amine  groups  and  protonation  of  amine  groups  re-
maining  in  the  PEI,  thereby  triggering  cytotoxicity. 
The group tested the targeted delivery and therapeu-
tic properties of NPs by additional conjugation with 
thiol-modified CTX and siRNA via succinimidyl es-
ter-PEG-maleimide  (NHS-PEG-MAL)  linkages.  In Theranostics 2012, 2(1) 
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vitro MRI scans of C6 cells incubated in the presence 
of the NP-PEI-siRNA-CTX exhibited intracellular up-
take  that  was  higher  than  that  observed  for 
NP-PEI-siRNA, suggesting that the presence of CTX 
on the NP surfaces facilitated cellular internalization 
of  the  nanovectors.  Gene  silencing  effects  indicated 
CTX-mediated  selectivity.  The  extent  of  GFP  gene 
expression  by  cells  incubated  with 
NP-PEI-siRNA-CTX  at  pH  6.2  was  significantly  re-
duced,  whereas  GFP  gene  expression  was  almost 
unchanged in cells treated with the same nanovector 
at pH 7.4. These results suggested that the nanovector 
system has a good safety profile and may potentially 
be used as a brain tumor targeted theranostic agent. 
Integrin αvβ3 is an ideal vascular target receptor 
because it is highly expressed on angiogenic endothe-
lium, and expression of this receptor on tumor vessels 
correlates with disease progression [83]. The targeting 
of molecular imaging agents or therapeutic delivery 
agents to integrin αvβ3 provides an attractive strategy 
for the treatment of cancer. Cheresh et al. used an ar-
ginine-glycine-aspartic acid (RGD) peptide sequence, 
an effective targeting molecule for integrin αvβ3, to 
fabricate liposomal Dox for treating metastatic disease 
[84].  RGD-immobilized  liposomes  were  synthesized 
from  distearoylphosphatidylcholine  (DSPC),  choles-
terol,  dioleoylphosphatidylethanolamine  (DOPE), 
distearoylphosphatidylethanolamine 
(DSPE)-mPEG2000, and DSPE-cyclic RGDfK via de-
hydration/rehydration  and  sonication.  Dox  was 
added  to  the  liposomes  at  55°C  to  provide 
RGD-Dox-NPs (Figure 5A). Mice containing s.c. Mat-
rigel plugs loaded with basic fibroblast growth factor 
(bFGF)  were  injected  intravenously  with  the 
RGD-Dox-NPs  (targeted)  or  RAD-Dox-NPs  (nontar-
geted).  After  7  days,  animals  treated  with 
RGD-Dox-NPs displayed vascular pruning compared 
with  the  normal  vascular  structure  of  PBS-treated 
animals, whereas RAD-Dox-NPs showed only a mar-
ginal reduction in neovascularization relative to the 
control  animals  (Figure  5B),  demonstrating  strong 
antiangiogenic  effects  of  the  integrin  αvβ3-targeted 
nanoparticles. Furthermore, RGD-Dox-NPs produced 
a  modest  reduction  of  the  primary  tumor  growth 
(23%) and a significant reduction of metastasis (82%) 
in an orthotopic pancreatic tumor model that includ-
ed metastatic lesions in the hepatic hilar lymph node 
(Figure 5C). On the other hand, RAD-Dox-NPs or free 
Dox did not provide apoptotic effects. These results 
suggest  that  integrin-targeted  nanoparticles  influ-
enced the invasive behavior of the primary tumor and 
its ability to metastasize. 
 
Figure 5. (A) Schematic representation and TEM image of RGD-Dox-NP (scale bar indicates 100 nm). (B) Vascular dis-
ruption in the mouse Matrigel model with intravenous injection of PBS or αvβ3-targeted RGD-Dox-NPs on days 1, 3, and 
5. After treatment, mice were intravenously injected with fluorescein-labeled G. simplicifolia lectin, and the plugs were 
removed and imaged by scanning confocal microscopy. (C) Suppression of metastasis in an orthotopic model of pancreatic 
cancer. After surgical implantation of the cells, mice were treated on days 5, 7, and 9 with RGD-Dox-NPs, RAD-Dox-NPs, 
free Dox, or PBS (each with 1 mg/kg total Dox per dose). On day 11, the primary tumor and the hepatic hilar lymph node 
were resected and weighed. Reproduced with permission from ref. [84]. Theranostics 2012, 2(1) 
 
http://www.thno.org 
12 
 
Figure 6. Schematic illustration of the silica nanoporous particle-supported lipid bilayer, depicting the disparate types of 
therapeutic and diagnostic agents that can be loaded within the nanoporous silica core, as well as the ligands that can be 
displayed on the surface of the nanoparticle. Reproduced with permission from ref. [86]. 
 
Lee et al. decorated liposomal Dox with a lung 
tumor targeted peptide [85]. Lung cancer is the lead-
ing cause of death due to cancer, and its high mortal-
ity rate appears to derive from a low therapeutic in-
dex for chemotherapy and late detection due to a lack 
of sensitive diagnostic biomarkers [2]. The identifica-
tion of novel biomarkers for early lung cancer detec-
tion remains a challenge. In this study, a novel pep-
tide (CSNIDARAC) with a high binding affinity for 
lung tumors was identified by in vitro screening of a 
phage  display  peptide  library,  and  CSNIDARAC 
peptide-conjugated  liposomal  Dox  (Lipo-Dox)  was 
synthesized. The in vivo tumor targeting capabilities 
and  the  therapeutic  efficacy  were  evaluated  in  the 
H460 tumor xenograft mice. To minimize the interac-
tions between the targeted peptide and the surface of 
the liposome, the amount of PEG on the surface of the 
liposome was reduced from 5–20 mol% (general use) 
to 1.3 mol% of total lipids. Tumor growth inhibition of 
the peptide-targeted Lipo-Dox was superior to that of 
the untargeted Lipo-Dox or free Dox administered at 
an  equivalent  dose,  and  this  result  was  consistent 
with  the  levels  of  apoptosis  measured  by  TUNEL 
staining.  Near-IR  Cy7.5  dye-labeled  pep-
tide-conjugated Lipo-Dox also showed a distinct flu-
orescence  signal  at  the  tumor,  whereas  untargeted 
Lipo-Dox did not show such a strong signal intensity, 
suggesting  the  potential  utility  of  this  lung  tu-
mor-targeting peptide as a diagnostic agent. 
Nanoporous  silica  offers  a  higher  surface  area 
and binding capacity for therapeutic and diagnostic 
agents  compared  to  similarly  sized  liposomes,  and, 
therefore,  provides  an  attractive  drug  delivery  sys-
tem. Multicomponent cargos are easily loaded onto 
nanoporous silica cores, and the resultant nanocarri-
ers can potentially be used for targeted multicompo-
nent  delivery.  Ashley  et al.  developed  porous  silica 
nanoparticle-supported  lipid  bilayers  (protocells, 
100–150  nm  in  diameter)  that  synergistically  com-
bined the features of mesoporous silica particles and 
liposomes to address the multiple challenges of tar-
geted delivery (Figure 6) [86]. Protocells were modi-Theranostics 2012, 2(1) 
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fied with an SP94-targeted peptide that binds to hu-
man  hepatocellular  carcinoma  and  a  histidine-rich 
fusogenic peptide that promotes endosomal escape of 
the protocells and cytosolic dispersion of the encap-
sulated cargos. The nanoporous support resulted in 
greater stability and enhanced lateral bilayer fluidity 
compared with both liposomes and non-porous par-
ticles,  thereby  promoting  multivalent  interactions 
between the protocell and the target cancer cell using 
a minimal number of targeting peptides via peptide 
recruitment to the cell surface. The high surface area 
and  porosity  of  their  nanoporous  cores  conveyed  a 
one-thousand-fold  higher  capacity  of  the  protocells 
for  Dox  than  the  similarly  sized  liposomes.  The 
unique properties of protocells solve the problem of 
simultaneously  achieving  high  targeting  specificity, 
high cytotoxicity toward the target cell, and low col-
lateral damage to non-cancerous cells. Cell viability 
tests  indicated  that  Dox-loaded  protocell  treatment 
maintained greater than 90% normal hepatocyte via-
bility while killing nearly 97% MDR1+ hepatocellular 
carcinoma  (Hep3B).  In  contrast,  Dox-loaded  lipo-
somes or protocells without fluidity on their surface 
were less efficient at killing Hep3B and caused con-
siderable  cytotoxicity  to  non-cancerous  cells.  The 
Dox-loaded protocells demonstrated good therapeu-
tic ability compared to both free Dox and Dox-loaded 
liposomes. 
Ruoslahti et al. described self-amplifying tumor 
homing nanoparticles [87]. The system was based on a 
CREKA  peptide  that  not  only  recognizes  clotted 
plasma proteins around tumor vessel walls or tumor 
stroma  but  also  induces  localized  tumor  clotting 
[88-90].  Fluorescein-labeled  peptides,  including  the 
sulfhydryl group of the single cysteine residue, were 
coupled to amino dextran-coated iron oxide nanopar-
ticles (CREKA-SPIO), and nanoparticles with at least 
8,000 peptide molecules per particle were used for in 
vivo experiments. To reduce reticuloendothelial sys-
tem (RES) uptake, a major obstacle to the homing of 
the  nanoparticles,  chelated  Ni2+-liposome  or  lipo-
somes  as  potential  decoy  particles  were  introduced 
prior  to  CREKA-SPIO  injection.  CREKA-SPIO  treat-
ment after pretreatment with the decoy particles dis-
played primary localization in the tumor vessels, and 
fewer  particles  were  seen  in  the  liver.  The  tu-
mor-targeted nanoparticles were distributed along a 
meshwork in the clots, presumably formed by fibrin, 
suggesting  that  the  nanoparticles  infiltrated  the 
depths  of  the  clots.  The  tumor  magnetization  was 
quantitatively  analyzed  using  a  superconducting 
quantum interference device (SQUID), revealing that 
heparin  injection  prior  to  injection  of  CREKA-SPIO 
reduced the tumor accumulation of nanoparticles by 
>50% by eliminating intravascular clotting, although 
the treatment series did not considerably reduce the 
number of vessels. Thus, binding of CREKA-SPIO to 
tumor  vessels  did  not  require  clotting  activity,  but 
intravascular clotting attracted more nanoparticles to 
the tumor, suggesting that tumor targeting was am-
plified. 
A  disease-targeting  multifunctional  integrated 
nanosystem  can  be  constructed  by  combining  two 
different  functional  nanoparticles  that  communicate 
with one another to amplify tumor targeting in vivo. 
Bhatia  et  al.  designed  communicating  nanosystems 
using  ‘signaling’  modules  (gold  nanorods,  NRs,  or 
tumor-targeted  tissue  factor,  tTF)  as  selective  tu-
mor-activating  agents  and  ‘receiving’  nanoparticles 
(magnetofluorescent iron oxide nanoworms, NWs, or 
Dox-loaded  liposomes,  LPs)  as  targeted  imaging  or 
therapeutic agents (Figure 7A) [91]. NWs, which were 
previously developed by Bhatia et al., are elongated 
nanostructures formed by the assembly of iron oxide 
cores that exhibit strong magnetic properties and effi-
cient tumor targeting [92]. As shown in Figure 7B, two 
‘signaling’ modules specifically activated the coagu-
lation cascade in tumors to broadcast the tumor’s lo-
cation to receivers in circulation. The NRs passively 
targeted tumors and converted external electromag-
netic energy into heat to locally disrupt tumor vessels. 
tTF, which included the RGD peptide motif, induced 
coagulation upon binding to the angiogenic αvβ3 re-
ceptors. The receiving nanoparticles targeted regions 
of coagulation. NWs and LPs were derivatized with a 
peptide  substrate  for  the  coagulation  transglutami-
nase FXIII or a fibrin-binding peptide. After injecting 
the  signaling  modules  into  MDA-MB-435  bearing 
mice, at 45°C, the ‘receiving’ NWs or LPs indicated 
prominent  extravascular  accumulation  around  the 
tumor  and  amplified  the  therapeutic  outcome  (Fig-
ures  7C  and  7D,  respectively),  demonstrating  a 
heat-dependent increase in the passive accumulation 
and specific biochemical recognition of the coagula-
tion process. Communication through the coagulation 
cascade improved the accumulation of the receiving 
modules in tumors by a factor of 40 relative to the 
receiving modules without communication. 
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Figure  7.  (A)  Schematic  representation  of  nanoparticle  communication  to  achieve  amplified  tumor  targeting.  Tu-
mor-targeted signaling nanoparticles (blue) broadcast the tumor location to the receiving nanoparticles (red) present in 
circulation. (B) Shown are the harnessing of the biological cascade to transmit and amplify nanoparticle communication and 
the molecular signaling pathway between the signaling and receiving components. (C) Thermographic images of the pho-
tothermal NRs with heating. Seventy-two hours after NR or saline injection, mice were co-injected with FXIII-NWs and 
untargeted  control-NWs,  and  their  right  flanks  were  broadly  irradiated  (top).  Twenty-four  hours  post-irradiation, 
whole-animal fluorescence imaging revealed the distribution of the receiving nanoparticles (bottom). (D) Amplified tumor 
therapy with communicating nanoparticles. Tumor volumes following a single treatment with the communicating nano-
particle systems and controls. Reproduced with permission from ref. [91]. 
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Figure 8. (A) Schematic diagram showing bioconjugation of HAuNS-siRNA and photothermal-induced siRNA release. (B) 
Schematic diagram showing the synthesis of F-PEG-HAuNS-siRNA and the proposed intracellular events following near-IR 
irradiation. (C) Effect of p65 siRNA photothermal transfection combined with irinotecan delivered to nude mice bearing 
HeLa cancer xenografts. (D) Micro-PET/CT imaging of nude mice bearing HeLa cervical cancer xenografts in right rear leg 6 
h after intravenous injection of F-PEG-HAuNS-siRNA(DOTA-
64Cu) or PEG-HAuNS-siRNA(DOTA-
64Cu). Arrowheads 
indicate the tumors. Reproduced with permission from ref. [98]. 
 
 
 
Figure 9. (A) Schematic diagram showing the preparation of Apt-hybr-TCL-SPIONs and Dox@Apt-hybr-TCL-SPIONs. (B) 
T2-weighted fast spin echo images at the level of the LNCaP tumor on the right side of the mouse taken 0, 2, 24, and 48 h 
after injection of Apt-hybr-TCL-SPIONs or scrApt-hybr-TCL-SPIONs. The dashed circle indicates the xenograft tumor 
region. (C) The RSE (%) in the tumor areas of the Apt-hybr-TCL-SPION- and scrApt-hybr-TCL-SPION-treated mice were 
recorded from the T2-weighted images as a function of time. Reproduced with permission from ref. [123]. Theranostics 2012, 2(1) 
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Small molecule-based targeting 
Small  molecules  with  infinitely  diverse  struc-
tures and properties are inexpensive to produce and 
have great potential as a class of targeting moieties. 
One of the most widely studied small molecules as a 
targeting moiety for the delivery of agents is folic acid 
(folate). Folate is a water-soluble vitamin B6 and is 
essential  in  humans  for  rapid  cell  division  and 
growth,  especially  during  embryonic  development 
[69]. In cancers, folate receptors are overexpressed on 
tumor cells, so folate, which has a high binding affin-
ity  for  the  folate  receptor  (Kd =  10–9  M)  enables  the 
targeted delivery of imaging and therapeutic agents 
to  tumors.  111In-DTPA-folate,  99mTc-folate  conjugate 
(EC20), folate-linked fluorescent hepten (EC17), and 
diacetylvinylblastine  hydrazide-folate  conjugate 
(EC145) are currently being tested in clinical trials as 
cancer  imaging  agents  and  therapeutics.  Folate  has 
been combined with drug delivery vehicles or inor-
ganic  nanoparticles  to  produce  targeted  delivery  of 
theranostic agents. Carbohydrates form another class 
of  small  molecule  targeting  ligands  that  selectively 
recognize  cell  surface  receptors,  such  as  lectin  [93]. 
The asialoglycoprotein receptor (ASGP-R) is present 
only on hepatocytes at a high density of 500,000 re-
ceptors per cell [94,95], and it readily binds carbohy-
drates, such as galactose, mannose, arabinose, which 
can thereby serve as effective liver-targeted drug de-
livery systems in vivo [96,97].  
Li et al. designed folate receptor-targeted hollow 
gold nanospheres carrying siRNA recognizing NF-κ
B, a transcription factor related to the expression of 
genes involved in tumor development [98,99]. In this 
case,  the  photothermal  effects  of  gold  nanospheres 
were utilized to regulate drug release and as a thera-
peutic tool. Core/shell-structured hollow gold nano-
spheres (HAuNS, 40 nm) were initially synthesized, 
consisting of a thin gold wall with a hollow interior, 
and the structures displayed strong surface plasmon 
resonance  (SPR)  tunability  in  the  near-IR  region 
[100-103].  Thiol-modified  siRNA  duplexes  directed 
toward the NF-κB p65 subunit were then introduced 
to the surface of HAuNS. Folates were coupled to the 
nanoparticles through a thioctic acid-terminated PEG 
linker to produce F-PEG-HAuNS-siRNA (Figure 8A 
and 8B). Irradiation with a pulsed near-IR laser (800 
nm)  altered  the  absorption  spectra  of  the 
HAuNS-siRNA  solutions  significantly,  indicating  a 
loss in the structural integrity and triggering the dis-
sociation of siRNA from HAuNS, when demonstrated 
by  TEM  and  fluorescence  microscopy  images.  This 
mode of action is termed ‘photothermal transfection’. 
Intravenous  injection  of  the  nanospheres  into  HeLa 
xenografts resulted in the distinct downregulation of 
the NF-κB p65 subunit only for the folate-conjugated 
nanosphere  treatment  combined  with  near-IR  laser 
irradiation,  suggesting  that  selective  targeting  and 
endolysosomal escape of the nanoparticles was acti-
vated by near-IR irradiation at the tumor site. In vivo 
tests,  in  which  therapy  was  combined  with  admin-
istration of irinotecan, a chemotherapeutic agent that 
increases  sensitivity  to  NF-κB  inhibition,  yielded  a 
substantially  enhanced  apoptotic  response  (Figure 
8C).  In  vivo  micro-positron  emission  tomography 
(PET))/computed  tomography  (CT)  imaging  also 
confirmed  the  folate-mediated  tumor-targeted 
theranostic  properties  of  the  nanostructures  (Figure 
8D). Although significant uptake of the nanoparticles 
was observed in the liver, spleen, kidney, and lung, no 
significant downregulation of p65 in these organs was 
observed  as  a  result  of  the  tumor-selective  near-IR 
irradiation.  
Riboflavin  is  an  essential  vitamin  for  cellular 
metabolism, and the riboflavin carrier protein (RCP) 
is  highly  upregulated  in  metabolically  active  cells 
[104,105].  Thus,  flavin  mononucleotide  (FMN),  an 
endogenous RCP ligand, was used as a small mole-
cule targeting ligand for metabolically active cancer or 
endothelial  cells.  Kiessling  and  co-workers  synthe-
sized FMN-coated ultrasmall superparamagnetic iron 
oxide nanoparticles (FLUSPIO) as MRI/optical dual 
probes for cancer detection [106]. USPIO was coated 
with  FMN  through  the  phosphate  groups  of  FMN, 
and guanosine monophosphate was added to stabi-
lize  the  colloid.  The  hydrodynamic  radius  of 
FLUSPIO was 97 ± 3 nm, and an intense fluorescence 
emission band was observed at 530 nm due to FMN. 
In vitro cellular uptake of FLUSPIO was investigated 
by  MRI  (3T),  TEM,  and  fluorescence  microscopy  of 
PC3  cells  and  HUVEC  cells.  Both  PC3  cells  and 
HUVEC cells showed a significantly higher R2 relax-
ation  rate  after  1  h  incubation  with  FLUSPIO  than 
with  nontargeted  USPIO.  Such  an  uptake  was  con-
siderably  reduced  by  competitive  blocking  of  RCP 
with  free  FMN.  A  strong  green  fluorescence  in  the 
cells  was  observed  after  FLUSPIO  incubation.  The 
perinuclear fluorescence signal suggested endosomal 
localization of the nanoparticles, consistent with TEM 
results, suggesting that FMN could serve as a versatile 
building block for generating tumor-targeted imaging 
and therapeutic modalities. 
Jeong  et  al.  demonstrated  the  use  of  galac-
tose-conjugated SPIONs as a hepatocyte-targeted dual 
contrast  agent  (nuclear  imaging/  MRI)  in  a  mouse 
model  [107].  Generally,  SPIONs  are  nonspecifically 
phagocytosed  or  endocytosed  by  RES  in  the  liver, 
spleen, lymph, and bone marrow after i.v. injection. Theranostics 2012, 2(1) 
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Therefore, hepatocyte-selective imaging was needed 
for the evaluation of hepatocytic function under cer-
tain clinical conditions, such as partial liver transplant 
or  hepatitis,  as  well  as  for  monitoring  the  disease 
progress. This research group synthesized lactobionic 
acid-  (LBA)  with  a  high  affinity  for  ASGP-R,  and 
immobilized the LBA onto SPIONs via amide linkages 
between  the  dopamine-modified  SPIONs  bearing  a 
primary amine group and the lactobionic acid using 
1-ethyl-3-(3-(dimethylamino)-propyl)  carbodiimide/ 
N-hydroxysuccinimide  (EDC/NHS)  chemistry.  To 
radiolabel  nanoparticles  with  99mTC,  diethylene  tri-
amine pentaacetic acid (DTPA) was then conjugated 
to the remaining amine groups of dopamine-SPIONs. 
After tail vein injection, in vivo micro-single photon 
emission computed tomography (SPECT)/CT images 
and  T2-weighted  MR  images  indicated  that  the 
99mTC-LBA-SPION  mainly  accumulated  in  the  liver 
within a few minutes. A competition study involving 
blocking of the ASGP-R with free galactose showed a 
large  decrease  in  the  liver  uptake,  suggesting 
ASGP-R-mediated  uptake  of  99mTC-LBA-SPIONs. 
TEM analysis confirmed that the LBA-SPIONs were 
located in the mitochondrial matrix as well as in the 
cytoplasm, indicating ASGP-R-mediated internaliza-
tion of the nanoparticles into hepatocytes. 
Aptamer-based targeting 
Aptamers are small nucleic acid ligands (15–40 
bases) that bind to targets with high specificity due to 
the ability of the molecules to fold into unique con-
formations  with  three-dimensional  structures  [108]. 
Aptamers are identified via a selection processes sim-
ilar to phage display, involving the systematic evolu-
tion  of  ligands  by  exponential  enrichment  (SELEX) 
[109]. From libraries of 1015 random oligonucleotides, 
aptamers displaying high affinity and specificity for a 
target can be selected. This targeting moiety has po-
tential advantage over antibodies, such as the small in 
size (15 kDa), low immunogenicity, and easy scale-up 
preparation  without  batch-to-batch  variations.  To 
date,  more  than  200  aptamers  have  been  isolated 
[110,111].  Pegaptanib,  a  VEGF165  targeted  aptamer, 
was approved by the FDA in 2004 for the treatment of 
neovascular macular degeneration. AS1411, a nucleo-
lin targeted aptamer, is in phase II of clinical devel-
opment [112-114]. However, aptamers possess several 
deleterious properties, such as rapid blood clearance, 
largely due to nuclease degradation. To overcome this 
difficulty, pyrimidine modifications at the 2’-fluorine 
position  or  chemical  modifications  with  PEG  have 
been  used  to  enhance  the  bioavailability  and  phar-
macokinetic  properties  [115].  The  best-characterized 
aptamers  for  targeted  delivery  are 
2’-fluoro-pyridine-RNA  aptamers  generated  against 
the  extracellular  domain  of  prostate-specific  mem-
brane  antigen  (PSMA)  [116].  These  aptamers  have 
been used to deliver Dox [117], self-assembled poly-
meric  nanoparticles  [118-120],  and  QDs  [121].  Re-
cently,  the  PSMA  aptamer-siRNA  chimera  system, 
extended at the 3’ end to contain a complementary 
nucleotide  sequence  directed  toward  the  antisense 
strand of the siRNA, was generated [122]. 
Jon et al. designed a CG-rich duplex containing a 
PSMA  aptamer  conjugated  iron  oxide  nanoparticles 
as  a  prostate  cancer-specific  nanotheranostic  agent 
[123]. As shown in Figure 9A, simultaneous prostate 
tumor detection and therapy were achieved in vivo by 
conjugating the (CGA)7-elongated PSMA aptamers to 
complementary  oligonucleotides  (ONTs) 
(5’-(TCG)7-3’)  immobilized  thermally  cross-linked 
iron oxide nanoparticles (TCL-SPIONs). The resulting 
CG-rich  duplex  aptamer-hybridized  TCL-SPIONs 
enabled loading of multiple Dox molecules onto the 
nanoparticles (Dox@Apt-hybr-TCL-SPIONs). The size 
of the targeted nanoparticles was 65 ± 12 nm, as de-
termined by DLS, and the Dox molecules were pre-
sent on the surface at a concentration of 2.9 wt%. The 
drug release profile of Dox@Apt-hybr-TCL-SPIONs in 
plasma indicated the quick release of electrostatically 
associated drug molecules in the early stages and the 
subsequently gradual release of drug through degra-
dation  of  the  CG-rich  duplex-containing  PSMA  ap-
tamer  by  serum  nucleases,  demonstrating  that  the 
Dox molecules loaded in the nucleotides were quite 
stable. In vivo T2-weighted MRI showed the selective 
accumulation of Apt-hybr-TCL-SPIONs at the tumor 
site in LNCaP (PSMA+)-bearing xenograft mice with a 
48%  relative  signal  enhancement  (RSE).  The  signal 
drop  persisted  up  to  48  h,  indicating  PSMA  ap-
tamer-mediated  selective  targeting  (Figure  9B  and 
9C).  In  contrast,  scrambled  aptamer-hybridized  na-
noparticles  (scrApt-hybr-TCL-SPIONs)  as  a  negative 
control indicated a lower RSE (21%), and the signal 
drop gradually recovered from the tumor over 24 h, 
suggesting tumor targeting through an EPR effect. In 
vivo therapeutic efficacy also demonstrated the supe-
riority  of  the  Apt-hybr-TCL-SPIONs  and  suggested 
the possibility of enhancing the accuracy of treatment 
using MRI-guided real-time monitoring of the nano-
particles. 
Kim et al. reported cancer-targeted multimodal 
imaging  probes  capable  of  concurrent  radionuclide 
imaging, MRI, and fluorescence imaging in vivo [124]. 
Magnetic cobalt ferrite cores were encased by a silica 
shell  containing  fluorescent  rhodamine,  and  were 
modified  with  various  organosilicon  compounds, 
such  as  (MeO)3Si-PEG  or  3-aminopropyl  triethox-Theranostics 2012, 2(1) 
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ysilane. Further conjugation of the AS1411 aptamer as 
a  nucleolin-targeting  ligand  [125]  and 
p-SCN-Bn-NOTA  for  67Ga-citrate  incorporation  pro-
vided MFR-AS1411. Twenty-four hours after injection 
of the nanoparticles into C6-bearing nude mice, the 
specific  tumor  targeting  of  MFR-AS1411  was  ob-
served in radionuclide images via  67Ga radioactivity. 
In  contrast,  the  MFR-AS1411  mutant 
(MFR-AS1411mt)-administered  mice  showed  rapid 
clearance through the bloodstream. T2-weighted MR 
images  of  MFR-AS1411-injected  mice  also  showed 
black spots at the tumor site. These results were fur-
ther confirmed by ex vivo fluorescence imaging, and 
high fluorescence signals were obtained from the in-
testine,  liver,  and  tumors,  demonstrating  the  tu-
mor-specific accumulation of MFR-AS1411. This mul-
timodal  imaging  system  offers  the  benefits  of  com-
plementary modalities by eliminating the shortcom-
ings of individual imaging modalities, and it provides 
for a broad range of diagnostic and therapeutic im-
aging possibilities in human applications [126].  
A  newly  identified  anti-EGFR  aptamer  and  its 
specific  ‘escort’  and  internalization  properties  were 
demonstrated by Ellington et al. via conjugation with 
gold nanoparticles (GNPs) [127]. Aptamers specific to 
EGFR were identified by generating an RNA pool that 
spanned  62  random  sequence  positions.  Selective 
binding species were obtained after round 12, and one 
aptamer predominated (aptamer J18) with a Kd of 7 
nM. The aptamer J18 was conjugated to GNPs (20 nm) 
by coating the GNPs with capture ONTs, followed by 
hybridization of an extended aptamer complementary 
to the capture ONTs. A flow cytometry-based inter-
nalization assay and fluorescence microscopy results 
indicated that only specific binding was observed in 
the A431 cells incubated with the aptamer J18-GNPs 
at 37°C, demonstrating that aptamers directed toward 
cell surface EGFR could lead to the specific internali-
zation  of  GNP  via  receptor-mediated  endocytosis. 
This  finding  suggests  that  receptor-specific  nucleic 
acids  can  overcome  non-specific  absorption  and  in-
ternalization of GNPs, which convey chronic disad-
vantages during therapy.  
Others 
A major challenge to the use of siRNA in mam-
mals is the intracellular delivery to specific tissues and 
organs that express the target gene. The first demon-
strations of siRNA-mediated gene silencing in a hu-
man were achieved by Davis et al. using a targeted 
nanoparticle  delivery  system  (the  clinical  version  is 
denoted CALAA-01) [128]. In this system, a human 
transferrin protein was used as a targeting ligand for 
binding to the transferrin receptor, which is upregu-
lated in malignant cells [129]. The nanoparticles con-
sisted  of  a  cyclodextrin-containing  cationic  polymer 
(CDP), adamantane (AD)-terminated PEG (AD-PEG), 
and  transferrin-conjugated  AD-PEG  (AD-PEG-TF), 
which formed inclusion complexes with surface cy-
clodextrins to achieve steric stabilization and target-
ing,  respectively.  The  nanoparticles  delivered  an 
siRNA designed to reduce expression of the ribonu-
cleotide reductase (RRM2), an established anti-cancer 
target  (Figure  10A)  [130].  To  examine  whether  the 
targeted delivery system (70 nm diameter nanoparti-
cles)  provided  effective  delivery  of  the  functional 
siRNA to human tumors, Davis et al. treated biopsy 
specimens from three patients, all of whom had met-
astatic melanoma, with three dose regimens (18, 24, 
and 30 mg/m2 siRNA, indicated as A, B, and C, re-
spectively).  Among  the  stained  tumor  sections,  the 
C1post and C2post samples showed the highest intensi-
ty,  whereas  Apost  did  not  show  the  presence  of  the 
stain  (Figure  10B),  indicating  dose-dependent  accu-
mulation of the targeted nanoparticles in human tu-
mors. Tumor RRM2 mRNA and protein levels were 
measured  by  quantitative  real-time  re-
verse-transcriptase  polymerase  chain  reaction 
(qRT-PCR) and western blotting, respectively (Figure 
10C). Consistent with tumor staining results, the C2pre 
and  C2post  samples  provided  direct  evidence  for 
RRM2  mRNA  or  protein  reduction  after  siRNA 
treatment  with  the  nanoparticles. 
5’-RNA-ligand-mediated  rapid  amplification  of  the 
complementary  DNA  ends  (5’-RLM-RACE)  using 
PCR  techniques  confirmed  that  the  observed  thera-
peutic results could be attributed to an RNAi mecha-
nism. 
Hyaluronic acid (HA), a copolymer of N-acetyl 
D-glucosamine  and  D-glucuronic  acid,  is  a  widely 
used targeting macromolecule that can bind to cluster 
determinant  44  (CD44),  which  is  overexpressed  in 
various  tumors  [131-133].  Zhou  et al.  used  this  tar-
geting ligand to develop a thermo-responsive hybrid 
nanogel for simultaneous temperature sensing, cancer 
cell  targeting,  fluorescence  imaging,  and  combined 
chemo-photothermal  treatment  [134].  The  spherical 
hybrid  nanogel  was  prepared  by  templated  Ag  na-
noparticle synthesis using a thermo-responsive non-
linear  PEG-based  hydrogel  coating  as  a  shell,  HA 
immobilization  on  the  surface  via  strong  hydrogen 
bonding between HA and PEG oligomers, and finally, 
addition of AuCl4– to the hybrid nanogel to form a 
Ag-Au bimetallic core. The Ag-Au@PEG-HA hybrid 
nanogels showed a high drug loading capacity (46.5 
wt%) that was stabilized by hydrogen bonds between 
the ether oxygen atoms of the nonlinear PEG gel shell 
and  the  amide  groups  of  Temozolomide  (TMZ),  a Theranostics 2012, 2(1) 
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model  drug.  Confocal  imaging  revealed  a  signifi-
cantly  higher  fluorescence  intensity  in 
Ag-Au@PEG-HA  hybrid  nanogel-incubated  B16F10 
cells (CD44+) than in the nanogel without HA, indi-
cating  selective  tumor  targeting.  The  drug  release 
profile demonstrated that  near-IR irradiation gener-
ated  localized  heat  and  enhanced  drug  delivery  by 
promoting a gradual transition from a hydrophilic to 
a hydrophobic PEG network. This transition not only 
broke the PEG-TMZ bonds, but also reduced the mesh 
size of the nanogels, thereby promoting diffusion of 
the drug molecules from the nanocages. The effects of 
combined  chemo-photothermal  treatment  were  in-
vestigated by measuring the cell viability in B16F10 
cells  incubated  with  empty  or  TMZ-loaded  hybrid 
nanogels  and  submitted  to  near-IR  irradiation.  The 
combination of TMS and photothermal treatment was 
much  more  cytotoxic  than  other  chemotherapy  or 
photothermal  treatments  alone.  In  particular,  com-
bined  therapy  showed  a  substantially  higher  thera-
peutic  efficacy  than  the  additive  therapeutic  index 
achieved  from  chemo-  and  photothermal  therapies, 
suggesting  that  the  nanogels  displayed  synergistic 
effects. 
 
 
Figure  10.  (A)  Schematic  representation  of  the  transferrin  targeted  nanoparticle  system.  (B)  Confocal  images  of 
post-treatment biopsy sections from patients A, B, and C. Left, Au-PEG-AD stain; middle, DAPI stain; right, merged images. 
The abbreviations are as follows: epi, epidermis, m; melanophage; s, skin side; t, tumor side. (C) qRT–PCR and western blot 
analysis of RRM2 protein expression in patient samples C2pre and C2post. The asterisk denotes the archived samples; the 
dagger denotes the samples obtained during the trial. Reproduced with permission from ref. [128]. 
 
3. Methods of conjugating the functional 
moieties for nanoparticle fabrication 
A  broad  spectrum  of  chemical  approaches  has 
been used to conjugate targeting moieties, therapeutic 
molecules, or contrast agents to nanoparticle surfaces. 
These  methods  can  be  categorized  as  conventional 
bioconjugation  strategies  (direct  conjugation,  linker 
chemistry, physical interactions), click chemistry, or 
hybridization methods (Table 2). The primary goal of 
targeted  ligand  conjugation  is  to  bind  a  targeting 
moiety  without  losing  its  functionality  after  attach-
ment to the nanoparticle. For example, binding of an 
antibody to a nanoparticle without consideration for 
the recognition site can shield the functional regions 
and  reduce  the  targeting  properties.  Conjugated Theranostics 2012, 2(1) 
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therapeutic agents, such as drugs and siRNA, must be 
designed to release from a nanoparticle system after 
cellular uptake to show therapeutic effects. In the fol-
lowing  sections,  the  unique  advantages  and  draw-
backs of each strategy will be discussed, and several 
examples of the strategy, including decoration of iron 
oxide nanoparticle surfaces with the above-listed tar-
geting moieties will be highlighted.  
Conventional bioconjugation strategies 
Direct conjugation 
Direct  reaction  strategies  involve  nanoparticle 
surface  functionalization  with  amine,  aldehyde,  or 
active hydrogen groups. The functional groups on the 
nanoparticle  surfaces  depend  on  the  coating  layer 
applied  during  the  nanoparticle  preparation  steps. 
These  strategies  are  particularly  suitable  for  conju-
gating fluorescence dyes, chelators for nuclear imag-
ing,  or  drugs.  In  general,  antibody-based  or  pep-
tide-based  targeting  moieties  that  are  unmodified 
prior  to  conjugation  are  not  natively  reactive  with 
these nanoparticles. However, liposomes that include 
maleimides on their surfaces or GNPs can be used for 
direct  conjugation  with  thiol  group-containing  bio-
molecules, such as antibodies, peptides, or ONTs. 
 
Table 2. Methods of conjugating functional moieties during nanoparticle fabrication. Theranostics 2012, 2(1) 
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Nanoparticles functionalized with amine groups 
easily react with commercially available fluorescence 
dyes,  such  as  fluorescein  isothiocyanate  (FITC)  and 
the Cy5.5 NHS ester. Gu et al. described fluorescence 
dye-modified chitosan-coated magnetic nanoparticles 
as efficient cancer cell imaging probes [135]. Optical 
labeling of the nanoparticles was achieved by reacting 
the  primary  amine  groups  of  chitosan  with  the 
isothiocyanate groups of FITC, and the magnetic na-
noparticles were then coated with FITC-labeled chi-
tosan. Recently, near-IR fluorescent dyes, such as cy-
anine, have been the most commonly used contrast 
agents for biomedical applications. To develop dual 
imaging probes for cancer  in vivo, Jon et al. synthe-
sized  amine-modified  iron  oxide  nanoparticles  by 
reaction  between  the  carboxyl  group-containing 
polymer  coating  layer  on  a  nanoparticle  and 
2,2’-(ethylenedioxy)bis-(ethylamine) [136]. The Cy5.5 
NHS ester was then coupled to the amine-modified 
nanoparticles. The animal tumor was clearly visual-
ized by MRI and optical microscopy. As reported for 
use of the Cy5.5-labeled nanoprobe, the combination 
of MRI and near-IR fluorescence imaging can poten-
tially allow disease site mapping using MRI prior to 
surgical  resection,  and  real-time  imaging  guidance 
can be achieved using fluorescent imaging techniques 
by  delineating  the  tumor  margins  during  surgery 
[137,138].  Trimodal  imaging  probes  have  been  de-
signed by adding a third imaging modality to the dual 
MRI and optical imaging probes. As described above, 
cancer-targeted multimodal imaging probes capable 
of radionuclide imaging, MRI, and fluorescence im-
aging in vivo have been developed by Kim et al. [124]. 
First,  the  fluorescence  properties  were  achieved  by 
introducing a rhodamine-containing silica shell coat-
ing onto the magnetic cobalt ferrite core. The nano-
particles  were  then  further  modified  with 
3-aminopropyl  triethoxysilane  to  produce  an  amine 
functionality  on  the  surfaces.  The  isothiocyanate 
group  of  the  radioactive  67Ga  chelator, 
p-SCN-Bn-NOTA,  was  then  reacted  with  the 
amine-functionalized  nanoparticles.  67Ga  incorpora-
tion provided the final trimodal imaging probes.  
Aldehyde-functionalized nanoparticles can react 
directly with functional moieties containing a hydra-
zide  group  via  the  hydrazone  ligation  chemistry. 
Dawson et al. synthesized tumor-targeted multifunc-
tional viral nanoparticles using a stepwise assembly 
strategy based on an efficient hydrazone ligation re-
action  [139].  The  cowpea  mosaic  virus  (CPMV)  has 
recently  been  explored  as  a  nanoparticle  delivery 
system  for  a  number  of  diseases  targeting  applica-
tions, and its use has been demonstrated in the con-
text of biomedical imaging and targeted drug delivery 
[140-142]. In a study, CPMV was modified with sul-
fo-succinimidyl  4-formylbenzoic  acid  to  yield  ben-
zaldehyde-labeled CPMV. VEGFR-1 antagonist pep-
tides  that  included  a  hydrazide  moiety  at  the 
C-terminus, prepared by solid phase peptide synthe-
sis,  and  hydrazide-modified  PEG  molecules  were Theranostics 2012, 2(1) 
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then added to the benzaldehyde-labeled CPMV. This 
ligation strategy enabled the sequential introduction 
of different peptides in a ratio that was controlled by 
the reaction conditions, and the modular nature of the 
chemistry could be tailored for specific applications. 
The hydrazide-functionalized nanoparticles could be 
conjugated to anticancer drugs containing a carbonyl 
group.  Misra  et  al.  developed  a  magnetic 
drug-targeting carrier encapsulated by a thermosen-
sitive  smart  polymer  [143].  This  group  utilized  the 
acid-labile hydrazone bond in the drug carrier system 
to  achieve  pH-sensitive  drug  release.  As  shown  in 
Figure 11, the surfaces of the magnetic nanoparticles 
were  functionalized  with  3-mercaptopropionic  acid 
hydrazide  via  Fe-S  covalent  bonding.  The  carbonyl 
group of Dox was chemically adsorbed to the mag-
netic  nanoparticle  surfaces  through  a  hydrazone 
bond.  The  Dox-loaded  magnetic  nanoparticles  were 
then  encapsulated  with  a  thermosensitive  biode-
gradable polymer to enable the on–off drug triggering 
mechanism. The release of drug followed the collapse 
of the thermosensitive polymer and the cleavage of 
the acid-labile hydrazone linkage. The proposed car-
rier is useful as a magnetic drug targeting system with 
a  drug  release  profile  that  could  be  controlled  by 
changes in the external temperature and pH. 
Recently, Chen and Sun et al. used the Mannich 
reaction to couple biomolecules to nanoparticles [144]. 
In this work, iron oxide nanoparticles functionalized 
with active hydrogen groups were reacted with amine 
group-containing  cyclic  RGD  peptides  to  develop 
ultrasmall  c(RGDyK)-coated  Fe3O4  nanoparticles 
(with an 8.4 ± 1.0 nm hydrodynamic diameter) as in 
vivo tumor-targeted imaging agents. Nonspecific up-
take  of  the  iron  oxide  nanoparticles  by  RES  in  the 
blood stream complicates the development of small 
biocompatible  nanoparticles with targeting capabili-
ties. Initially, they synthesized Fe3O4 nanoparticles via 
the thermal decomposition of Fe(CO)5 in benzyl ether 
in  the  presence  of  4-methylcatecol,  as  a  surfactant, 
followed  by  air  oxidation.  The  4-methylcatecol 
formed a tight thin coating layer over the nanoparticle 
surface via formation of a strong chelating bond be-
tween  the  iron  and  the  catechol  unit.  The  aromatic 
ring of the 4-methylcatecol on the nanoparticles was 
directly  coupled  with  the  amine  group  of  a  lysine 
residue in the cyclic RGD peptide, c(RGDyK) (Figure 
12). High-resolution transmission electron microsco-
py (HRTEM) images of the nanoparticles indicated an 
iron  oxide  core  size  of  4.5  nm  and  a  coating  layer 
containing the c(RGDyK) peptide 2 nm in thickness, 
close to the size in water. 
The  simple  process  of  preparing  functional 
group-immobilized liposomes has facilitated the cou-
pling of biomolecules to liposomal surfaces without 
the need for complex surface coating steps. In partic-
ular,  liposomes  functionalized  with  thiol-reactive 
maleimide  groups  may  be  easily  prepared  using 
commercially  available  maleimide-modified  phos-
pholipids  in  the  liposome  preparation  step.  Immu-
noliposomes  are  commonly  synthesized  by  direct 
bioconjugation  between  maleimide-modified  lipo-
somes  and  thiol  group-containing  antibody  frag-
ments. As described above, lung cancer targeting lip-
osomes fabricated using an anti-c-Met antibody were 
prepared  via  the  conjugation  of  a  cysteine  resi-
due-fused  anti-c-Met  scFv  antibody  to  the  malei-
mide-modified  PEG-terminated  liposomal  Dox  [64]. 
In another case, Mulder et al. reported the preparation 
of  integrin  αvβ3-targeted  paramagnetic  lipid-coated 
silica nanoparticles with a QD core as a novel contrast 
agent platform [145]. QDs were encapsulated by silica 
spheres via the reverse micelle method, and the silica 
surface  was  coated  with  hydrophobic  octadecanol. 
Addition of a mixture of phospholipids (PEG-DSPE, 
maleimide-modified  PEG-DSPE,  and 
Gd-DTPA-bis(stearylamide))  yielded  water-soluble 
QD/silica  nanoparticles  enclosed  by  a  lipid  mono-
layer. The thiol moieties of the hydroxylamine pre-
treated  cyclic  RGD  peptides 
(c(RGDf(-S-acetylthioacetyl)K))  were  conjugated  to 
the surfaces of the maleimide groups on the nanopar-
ticles to obtain integrin-targeted multimodal imaging 
probes.  
GNPs  can  couple  to  thiol-modified  functional 
moieties  without  the  need  for  additional  functional 
groups.  Because  Au  is  highly  reactive  toward  thiol 
groups, forming a strong Au-S bond, a variety of thi-
ol-functionalized biomolecules may be conjugated to 
GNP surfaces in a straightforward manner. Oligonu-
cleotide-based molecules, such as siRNA, are usually 
chemically synthesized to contain sulfhydryl groups 
that can then be conjugated to GNPs. When Li et al. 
synthesized the folate-receptor targeted hollow gold 
nanospheres  carrying  siRNA,  they  conjugated  thi-
ol-modified siRNA duplexes directly to the surfaces 
of HAuNS [98]. 
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Figure 11. Schematic diagram of the sequence of steps in the synthesis of a magnetic drug targeted carrier encapsulated in 
a thermosensitive smart polymer, and the drug release process. Reproduced with permission from ref. [143]. 
 
 
Figure 12. Schematic illustration of the coupling of the c(RGDyK) peptide to Fe3O4 nanoparticles. Reproduced with 
permission from ref. [144]. 
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Linker chemistry 
Linker molecules can control the binding orien-
tations  of  ligands,  thus,  bioconjugation  via  linker 
chemistry is preferred over direct conjugation strate-
gies for the attachment of targeting moieties to nano-
particles. Antibodies, peptides, and small molecules 
may be conjugated to nanoparticles using a variety of 
linkers. The most common linker chemistry relies on 
the  reaction  between  amine-modified  nanoparticles 
and  sulfhydryl-containing  biomolecules.  Cysteine 
residues may be present or introduced into proteins 
and peptides, or the peptide may be chemically mod-
ified to gain this functionality. For example, the pri-
mary amine groups of lysine residues can be thiolated 
using  Traut’s  reagent  (2-iminothiolane)  or  SATA 
(N-succinimidyl s-acetylthioacetate). This bioconjuga-
tion strategy has employed a variety of linker mole-
cules,  including  SIA  (N-succinimidyl  iodoacetate), 
SMCC  (succinimidyl-4-(N-maleimidomethyl)  cyclo-
hexane-1-carboxylate),  SPDP  (N-succinimidyl-3-(2- 
pyridyldithio)-propionate), or heterobifunctional PEG 
molecules  (NHS-PEG-MAL).  Heterobifunctional 
linker molecules include amine-reactive succinimidyl 
esters in one region of the molecule and thiol-reactive 
iodoacetate,  maleimide,  or  pyridyldithio  groups  on 
the other end. The reaction methods can form cova-
lent  complexes  between  nanoparticles  and  ligands, 
thereby requiring stepwise nanoparticle modification 
prior  to  ligand  attachment  or  purification  between 
each step [138]. Carboxyl group-presenting nanopar-
ticles  may  be  covalently  bonded  to  amine 
group-bearing  functional  moieties  through 
EDC/NHS linkers, which form an amide linkage. This 
approach is effective for the attachment of molecules 
that have a single amine group, although it is difficult 
to  control  the  binding  orientations  of  ligands  with 
multiple amines, often leading to loss of functionality 
of the targeting ligands. 
Ross et al. developed brain cancer-targeted mul-
tifunctional  polymeric  nanoparticles  consisting  of 
tumor vascular targeting F3 peptides, photosensitiz-
ers for photodynamic therapy (PDT), and iron oxide 
for MRI [146]. The targeted delivery of photodynamic 
agents  to  tumor  sites  via  nanoparticles  is  one  ap-
proach to overcoming the disadvantages of prolonged 
cutaneous photosensitization during PDT. To conju-
gate targeting peptides onto the nanoparticles specif-
ically, first, amine-functionalized, photofrin and iron 
oxide-encapsulated  polyacrylamide  nanoparticles 
were  prepared,  and  the  water-soluble  sulfo-SMCC 
was added to couple with surface amines on nano-
particles.  The  reaction  mixture  was  further  treated 
with  succinimidyl  succinate  ester  of  PEG2000.  And 
the  thiol  groups  of  F3  peptides,  pretreated  with 
Traut’s reagent, were lastly conjugated to the malei-
mide-functionalized  nanoparticles.  The  targeted  na-
noparticles performed well during PDT and signifi-
cantly  improved  survival  rate  in  a  glioma-bearing 
orthotopic rat model. SMCC may be replaced by het-
erobifunctional  PEG  molecules  (NHS-PEG-MAL)  to 
functionalize amine-modified nanoparticles. Zhang et 
al. used NHS-(PEG)2-MAL and NHS-(PEG)12-MAL to 
introduce maleimide functionalities onto the magnetic 
nanoparticles [81]. A thiol-modified siRNA and CTX 
were  attached  to  the  amine-functionalized 
pH-sensitive PEI-coated iron oxide nanoparticles via 
NHS-(PEG)2-MAL  and  NHS-(PEG)12-MAL,  respec-
tively (Figure 13A). The dodecaethyleneglycol linker 
for  CTX  facilitated  targeted  ligand  delivery  by 
providing a more flexible linker, thereby enhancing 
the  peptide’s  ability  to  bind  to  a  target  receptor. 
pH-sensitive  surface  coating  layers  improved  the 
presentation and availability of cationic CTX on the 
nanovector  surfaces  by  introducing  electrostatic 
charge repulsion between CTX and surface moieties 
(Figure 13B). 
Pyridyl disulfide linkers include cleavable disul-
fide bonds, which facilitates a quantitative evaluation 
of the reaction efficiency. Jon et al. calculated the con-
centration of surface-bound peptide molecules on the 
nanoparticles  by  quantifying  the  released  pyri-
dine-2-thione  [147].  In  an  effort  to  develop  integ-
rin-targeted  iron  oxide  nanoparticles  as  theranostic 
agents, amine-modified iron oxide nanoparticles were 
synthesized,  and  SPDP  was  added  to  convert  the 
primary  amine  groups  on  the  nanoparticles  to 
sulfhydryl-reactive  pyridyldisulfide  groups.  Conju-
gation between the thiol group-containing cyclic RGD 
peptides  and  the  SPDP-activated  nanoparticles  pro-
duced  pyridine-2-thione,  which  was  immediately 
collected by spin filtering (at 100 K). The immobilized 
cRGD molecules were quantified based on the ultra-
violet  (UV)  absorbance  at  343  nm  of  the  collected 
pyridine-2-thione filtrate, indicating that the average 
number of conjugated cRGD peptides on each nano-
particle  was  0.39  wt%.  This  linker  is  useful  for  en-
hancing the intracellular gene silencing properties of 
siRNA. Bhatia et al. studied the gene-silencing efficacy 
of  siRNA-conjugated  QDs  using  cleavable  (sul-
fo-LC-SPDP)  or  noncleavable  (sulfo-SMCC) 
cross-linkers [148]. They immobilized thiol-modified 
siRNA specific for EGFP to amine-functionalized QDs 
via sulfo-LC-SPDP or sulfo-SMCC linkers and quan-
tified  the  EGFP  fluorescence  intensity.  The  siRNA 
attached QDs via the sulfo-LC-SPDP linker provided 
greater silencing efficiency than those attached via the 
sulfo-SMCC  linker.  The  cleavable  disulfide Theranostics 2012, 2(1) 
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cross-linker  released  siRNA  from  the  nanoparticles 
into  the  intracellular  reducing  environment,  which 
affected the interactions between the siRNA and the 
RNA  induced  silencing  complex  (RISC),  which  is 
necessary for gene knockdown.  
Stable linkages between nanoparticles and func-
tional moieties may be provided by iodoacetate link-
ers.  Using  this  linker,  Zhang  et  al.  synthesized  a 
CTX-mediated  brain  tumor  targeting  magnet-
ic/optical  nanoprobe  [73].  As  shown  in  Figure  14, 
amine-functionalized nanoparticles were prepared by 
synthesizing a PEG-grafted chitosan polymer. Meth-
oxy-PEG was oxidized to yield PEG-aldehyde, which 
was then reacted with the primary amines of depol-
ymerized chitosan by formation of a Schiff base. Sub-
sequently, iron oxide nanoparticles were coated with 
a  PEGylated  chitosan-branched  copolymer  (NPCP). 
SATA-pretreated  CTX  was  then  conjugated  to  the 
nanoparticles via an SIA cross-linker. The nanoparti-
cles  were  linked  to  fluorescence  imaging  dyes  by 
conjugating the amine groups remaining on the iron 
oxide nanoparticles to a Cy5.5 NHS ester, producing 
NPCP-Cy5.5-CTX as a brain tumor targeting magnet-
ic/optical nanoprobe.  
Amine coupling using EDC/NHS chemistry is a 
practical  approach  to  conjugating  small  molecules, 
peptides,  and  ONTs.  EDC  reacts  with  the  carboxyl 
groups of nanoparticles to form an active ester, but 
this  reactive  complex  is  subject  to  rapid  hydrolysis 
under aqueous conditions. Formation of a sulfo-NHS 
ester  intermediate  prevents  hydrolysis  and  extends 
the half-life of the activated carboxylates, permitting 
their reaction with the primary amine groups of func-
tional moieties. As described above, Jeong et al. syn-
thesized  hepatocyte-targeted  LBA-immobilized 
SPIONs  via  an  amide  linkage  between  the  dopa-
mine-modified  SPION  bearings  a  primary  amine 
group and lactobionic acid using the EDC/NHS cou-
pling chemistry [107]. Jon and Farokhzad  et al. also 
developed prostate-targeted QD aptamer conjugates 
as theranostic agents by reacting carboxyl QDs with a 
5’-amine-modified  A10  PSMA  aptamer  via 
EDC/NHS chemistry [121].  
 
 
Figure 13. Schematic diagram showing the preparation of (A) the multifunctional NP-PEI-siRNA-CTX nanovector and (B) 
intracellular uptake, extracellular trafficking, and processing of the nanovector in tumor cells. Reproduced with permission 
from ref. [81]. 
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Figure 14. Synthesis of NPCP-Cy5.5-CTX nanoprobes. (A) PEG-grafted chitosan, (B) sulfhydryl functionalization of CTX, 
and (C) CTX and Cy5.5 conjugation to NPCP. Reproduced with permission from ref. [73]. 
 
 
Physical interactions 
Physical  interactions  encompass  electrostatic, 
hydrophobic, and affinity interactions. Physical con-
jugation strategies are particularly useful for the as-
sembly  of  therapeutic  agents  onto  nanoparticles. 
Electrostatic interactions are useful for loading siRNA 
onto nanoparticles coated with cationic PEI. Hydro-
phobic anticancer drugs can adsorbed via hydropho-
bic interactions onto nanoparticles coated with a hy-
drophobic coating layer, and the drugs may then be 
released inside cells after degradation of the coating 
layer.  Although  these  interactions  have  several 
unique advantages, including rapid binding and the 
lack of modification steps, it is difficult to control the 
molecular  orientations  of  physically  bound  ligands. 
This binding mode, therefore, is not appropriate for 
immobilizing targeting moieties. In contrast, affinity 
interactions are effective for bioconjugating targeting 
ligands to nanoparticles. A representative example of 
affinity interactions is the streptavidin–biotin interac-
tion.  This  linkage  is  very  stable  and  shows  the 
strongest known binding affinity among non-covalent 
linkage reactions (Kd= 4.0 × 10–14 M) [149].  
T  cell-specific  DGKα  genes  were  incorporated 
onto nanoparticles by Chen and Shuai et al. by first 
synthesizing  PEG-g-PEI-SPIONs  as  an  MRI-visible 
polymeric vector [60]. The PEG-g-PEI was coated onto 
the  SPIONs  using  the  ligand  exchange  method.  T 
cell-specific targeted gene delivery was achieved by 
preparing  T  cell-targeted  scAbCD3-PEG-COOH  con-
jugates. A thioether bond linked MAL-PEG-COOH to 
the  sulfhydryl-containing  scAbCD3,  and 
PEG-g-PEI-SPIONs were then added to the solution in 
the  presence  of  EDC/NHS  to  produce 
scAbCD3-PEG-g-PEI SPIONs. The targeting polyplexes 
(scAbCD3-PEG-g-PEI  SPIONs/DNA)  were  then  ob-
tained  by  loading  the  DGKα  gene  onto  the 
scAbCD3-PEG-g-PEI  SPIONs  via  electrostatic  interac-
tion. Park et al. designed a new class of siRNA struc-
ture,  multimerized  siRNA-linear  PEI  (LPEI)  com-
plexes, to achieve efficient gene silencing [150]. Thi-
ol-modified, single-stranded sense or antisense siRNA 
were  reacted  with  cleavable  or  noncleavable 
cross-linkers, were dimerized, and were annealed to 
obtain multi-siRNA. The multi-siRNA species formed 
stable compact nanosized complexes (81.8 ± 47.2 nm) 
with oppositely charged LPEI via electrostatic inter-
actions. Efficient gene silencing was promoted by the 
high  charge  density.  Multi-siRNA,  with  intracellu-
larly  cleavable  linkages,  displayed  the  capacity  for Theranostics 2012, 2(1) 
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target sequence-specific gene silencing. 
Labhasetwar  et  al.  developed  a  hydrophobic 
drug  carrier  system  using  a  water-dispersible  oleic 
acid-Pluronic-coated  iron  oxide  nanoparticle  formu-
lation  [151].  In  their  study,  Pluronic  F-127  was  an-
chored onto the oleic acid-coated iron oxide nanopar-
ticles to improve the dispersibility in aqueous solu-
tions,  and  hydrophobic  Dox  molecules  were  parti-
tioned into the oleic acid shell surrounding the iron 
oxide nanoparticles via hydrophobic interactions. The 
amount of Dox that could be loaded was 8.2 wt%. This 
formulation simplified the drug-loading process rela-
tive  to  chemical  conjugation  methods.  In  a  similar 
approach, Wei and Gao utilized this formulation to 
incorporate a hydrophobic anticancer drug, Dtxl, to 
the  prostate  tumor  targeted,  scAbPSCA-linked  multi-
functional polymeric vesicles [58]. They synthesized 
poly(lactic-co-glycolic) acid and entrapped both SPIO 
and  Dtxl  into  this  polymer.  At  this  time,  Dtxl  was 
loaded  into  the  oleic  acid/oleylamine  shell  of  the 
SPIO, and the drug loading was 6.0 wt%. The parti-
tion of the drug in the shell via hydrophobic interac-
tions, provided for a slow and controlled drug release 
profile from the multifunctional vesicles. Host–guest 
interactions provide another example of hydrophobic 
interactions. Cyclodextrin (CD) is the most common 
host molecule and displays a particular aptitude for 
enhancing the solubility of guest molecules, such as a 
hydrophobic  organic  solute,  by  encapsulating  it 
within  its  central  cavity  (in  the  shape  of  a  hollow 
truncated  cone).  Davis  et al. first  demonstrated  siR-
NA-mediated gene silencing in a human using a tar-
geted CD-based delivery system [128]. They synthe-
sized  a  β-CD-containing  cation  polymer  (CDP)  by 
polymerizing a difunctionalized β-CD monomer with 
a  difunctionalized  comonomer  using  dimethylsu-
berimidate·2HCl  and  dithiobis(succinimidyl  propio-
nate), and this polymeric backbone provided a scaf-
fold  for  attaching  agents  [152].  They  also  prepared 
adamantane  (AD)-PEG  by  conjugating  succinimidyl 
propionate-PEG5000 with the amine-containing AD. 
AD is a hydrophobic cage molecule that can fit inside 
the cavity of β-CD. In this case, the CD–AD interac-
tions  were  used  to  assemble  non-biofouling  PEG 
molecules  or  malignant  tumor  targeting  transferrin 
(Tf) ligands on the surface of the polymeric drug de-
livery  system.  To  the  coupled  complex  of  AD  and 
vinyl sulfone-PEG5000-NHS was coupled transferrin, 
via a lysine residue, to produce Tf-PEG-AD. Finally, 
Tf-PEG-AD  or  PEG-AD  was  incorporated  into  the 
CDP,  and  siRNA  was  condensed  onto  the  cationic 
polymeric systems to provide a targeted nanoparticle 
siRNA  delivery  system.  Interestingly,  transferrin 
formed  strong  complexes  with  nanoparticles  while 
maintaining its functionality. In addition to the  hy-
drophobic  interactions  contributing  to  the  complex 
stability,  van  der  Waals  interactions  and  hydrogen 
bonding assisted in the host-guest association.  
The  HER2/neu  protein  is  highly  expressed  in 
approximately 25% of human breast cancers, and ex-
pression  levels  of  the  protein  correlate  with  a  poor 
prognosis for breast cancer or other human cancers 
[153]. Artemov et al. examined the expression levels of 
HER2/neu  using  commercially  available  streptavi-
din-conjugated  superparamagnetic  iron  oxide  nano-
particles [154]. Breast cancer cells expressing different 
levels  of  the  HER2/neu  receptors  were  pretreated 
with biotinylated Herceptin, followed by nanoparti-
cles  targeted  to  the  receptors.  In  vitro  T2-weighted 
MRI  contrast  was  correlated  with  the  levels  of 
HER2/neu expression on the breast cell membrane, as 
confirmed by flow cytometry analysis. The noninva-
sive  imaging  method  was  highly  sensitive,  with  a 
lower limit of detection in the range of 5 × 104 recep-
tors per cell. This sensitivity is comparable to the typ-
ical expression levels of HER2/neu receptor in patient 
samples, in which levels can range from 105 to 4.5 × 
106 per cell.  
In addition to the physical interactions described 
above, other noncovalent secondary interactions can 
stabilize  bioconjugation.  Adriamycin,  such  as  Dox, 
may intercalate into the DNA double stranded helix 
via  guanine–cytosine  d(CpG)  site-specific  interac-
tions. The drug-DNA complex is stabilized by elec-
trostatic  hydrogen  bonds  and  stacking  π-bonding 
interactions  between  the  electron-deficient  qui-
nine-based chromophore and the electron-rich purine 
or pyrimidine bases [155]. Based on this specific in-
teraction, Jon  et al. designed a CG-rich duplex con-
taining  PSMA  aptamer-conjugated  GNPs  and  mag-
netic  nanoparticles  as  a  prostate  tumor  targeting 
theranostic agent [156, 123]. They demonstrated that a 
PSMA aptamer containing an appended (CGA)7 re-
peating ONT significantly enhanced the Dox-loading 
capacity compared to the original PSMA aptamer by 
providing binding sites for at least 6–7 Dox molecules 
in the extended region, whereas the original PSMA 
aptamer included only a single Dox molecule binding 
site. Conjugation of the elongated PSMA aptamer to 
nanoparticles proceeded by coating the nanoparticles 
with aptamer-binding ONTs comprising an A10 spacer 
and a 5’-(TCG)7-3’ complementary sequence. Once the 
PSMA aptamers had been conjugated onto the nano-
particles, several Dox molecules intercalated among 
the surface-bound CG-rich duplex containing a PSMA 
aptamer. The resulting nanoparticles displayed pros-
tate-targeted  diagnostic  and  therapeutic  abilities 
when  analyzed  by  CT  imaging/MRI  or  a  tu-Theranostics 2012, 2(1) 
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mor-bearing animal model.  
Click chemistry 
The  Huisgen  1,3-dipolar  cycloaddition,  also 
known  as  the  ‘click  reaction’  was  developed  by 
Sharpless  et  al.  almost  a  decade  ago  [157].  The 
Cu(I)-catalyzed  reaction  between  alkyne  and  azide 
groups  results  in  the  formation  of  a  stable  triazole 
linkage,  which  is  water-soluble  and  biocompatible. 
These reactions are highly specific and occur under 
mild  reaction  conditions  in  aqueous  solutions  with 
high  yield.  The  reaction  specificity  precludes  unde-
sirable reaction with other functional groups, ensur-
ing specific conjugation at the desired location on the 
biomolecules. These features provide highly oriented 
linkages, thus the click reaction is specifically suited 
for the conjugation of targeting moieties to the nano-
particles. However, the Cu(I) catalyst, needed to drive 
the  reaction,  can  cause  toxicity,  such  as  hepatitis, 
neurological  disorders,  kidney  disease,  or  Alz-
heimer’s disease in vivo [158]. Recently, Weissleder et 
al.  developed  a  covalent  bioorthogonal  reaction  be-
tween a 1,2,4,5-tetrazine (Tz) and a trans-cyclooctene 
(TCO) as the alternative coupling  mechanism [159]. 
The [4 + 2] cycloaddition is fast, chemoselective, does 
not  require  a  catalyst,  and  proceeds  in  serum.  This 
reaction strategy is therefore attracting increased in-
terest for molecular imaging applications at the cel-
lular level.  
Bhatia et al. firstly demonstrated the use of ‘click’ 
nanoparticles  for  in  vivo  applications  [160].  They 
synthesized  a  succinimidyl  4-azidobutyrate  and  al-
kyne-containing  Lyp-1  peptide  (CGNKRTRGC)  that 
binds  to  p32  mitochondrial  protein-overexpressing 
tumor  cells  [161].  The  succinimidyl  4-azidobutyrate 
was  then  linked  to  a  thiol-PEG5000-amine,  and  the 
product  was  added  to  N-[γ-maleimidobutyryloxy] 
succinimide  ester  (GMBS)-activated  magne-
to-fluorescent  nanoparticles  (MFNP),  consisting  of 
amine-functionalized  cross-linked  iron  oxide  nano-
particles linked to a cyanine dye (Vivo Tag 680), to 
generate  azido-PEG-nanoparticles.  The  al-
kyne-bearing Lyp-1 peptides were clicked to the na-
noparticles  in  the  presence  of  CuSO4  and  sodium 
ascorbate. Excess copper catalyst and peptides were 
removed using size exclusion chromatography. Nude 
mice bearing human MDA-MB-435 were injected in-
travenously  with  Lyp-1-iron  oxide  nanoparticles  to 
test in vivo tumor targeting properties. Twenty-four 
hours post-injection, the mice were sacrificed and the 
organs  were  collected  for  immunohistochemical  or 
whole organ fluorescence analysis. The Lyp-1 ‘click’ 
nanoparticles appeared to have extravasated from the 
tumor  vasculature,  penetrated  into  the  interstitial 
spaces  of  the  tumor,  and  bound  to  p32-expressing 
cells.  In  contrast,  non-targeted  az-
ido-PEG-nanoparticles were localized within the im-
mediate periphery of blood vessels by passive accu-
mulation. These results demonstrated the successful 
use of the ‘click’ attachment strategy in the develop-
ment of specific tumor targeting theranostic nanopar-
ticles. 
Perez et al. utilized the click reaction to conjugate 
folate  onto  multifunctional  iron  oxide  nanoparticles 
[162].  They  synthesized  poly(acrylic  acid) 
(PAA)-coated iron oxide nanoparticles and encapsu-
lated  lipophilic  fluorescence  dyes  (dialkylcarbocya-
nine  fluorophores)  within  the  hydrophobic  coating 
layers on the nanoparticles to provide dual imaging 
capabilities.  The  nanoparticles  were  functionalized 
with  alkyne  groups  via  a  reaction  with  propargyl 
amine and EDC/NHS, followed by further reaction 
with azide-containing folate via the click chemistry. A 
hydrophobic  anticancer  drug,  Taxol,  was  then  en-
capsulated  to  yield  multifunctional  theranostic  na-
noparticles.  A thick polymeric coating layer, 40 nm 
thick according to DLS measurements, played a key 
role  in  incorporating  hydrophobic  guest  molecules. 
The MTT and cellular uptake assessments indicated 
the folate-decorated nanoparticles’ specificity toward 
target tumor cells (A549). MRI studies demonstrated 
the  ability  of  those  theranostic  agents  to  behave  as 
sensitive MRI contrast agents.  
An alternative to the click reaction was reported 
by  Weissleder  et  al.,  who  described  the  use  of  a 
bioorthogonal chemistry-based targeting nanoparticle 
platform [163]. This chemistry permitted reconfigura-
tion of the conjugation strategies for targeting nano-
particle sensors, thereby improving the binding effi-
ciency and detection sensitivity. This technique was 
referred to as ‘bioorthogonal nanoparticle detection’ 
(BOND)  (Figure  15A).  Their  study  compared  two 
BOND  assays  to  determine  the  specific  cancer  cell 
targeting ability (Figure 15B). In one setting, MFNPs 
were directly coupled  to three types  of monoclonal 
antibody  (mAb)  prior  to  cell  exposure  (BOND-1). 
Another  setting  examined  a  two-step  strategy 
(BOND-2), in which TCO-functionalized monoclonal 
antibodies  mediated  primary  binding  to  cells  and 
were coupled to Tz-immobilized MFNPs via the co-
valent  bioorthogonal  reaction.  In  this  comparison, 
amino-MFNPs were modified with Tz-NHS to create 
Tz-MFNP, and lysine groups of the mAbs (anti-HER2 
Abs, anti-EpCAM Abs, and anti-EGFR Abs) reacted 
with the TCO-NHS to produce TCO-mAbs. Nanopar-
ticle binding  increased with increased TCO loading 
until saturation at 20 TCO per antibody. Interestingly, 
the  BOND-2  labeling  strategy  consistently  yielded Theranostics 2012, 2(1) 
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higher nanoparticle binding to cells compared to di-
rect  labeling  such  as  maleimide/thiol  chemistry  or 
BOND-1  (Figure  15C).  These  results  suggested  that 
TCO-decorated mAbs may serve as scaffolds for sub-
sequent nanoparticle attachment and can amplify the 
achievable signal by increasing the number of availa-
ble TCO reaction sites. In addition, when compared 
with  strepavidin-biotin  coupling  mechanism  as 
two-step  labeling  strategy,  the  overall  signal  was 
considerably  lower  than  BOND-2,  confirming  the 
unique  and  superior  bioorthogonal  chemistry.  The 
higher  probability  of  binding  was  attributed  to  the 
valency and small size of Tz, which interacted with 
TCO  on  the  antibody  surfaces  without  introducing 
steric  hindrance.  Recently,  it  has  been  shown  that 
BOND amplification can be used as a technique for 
detecting intracellular proteins in rapid sensitive di-
agnostic  applications  [164].  The  detection  of  cyto-
plasmic and nuclear protein markers (cytokeratin, CK, 
and  Ki-67,  respectively)  as  model  diagnostic  targets 
was tested by examining several methods for fixing 
and  permeabilizing  cells,  and  a  combination  of 
freeze–thaw cycles and saponin treatment provided 
the best results, with a small increase in background 
binding  (Figure  16A).  As  described,  the  BOND-2 
scheme amplified nanoparticle binding to intracellu-
lar targets with an order of magnitude higher signal 
compared  to  the  BOND-1  scheme.  This  procedure 
permitted quantification of the target protein expres-
sion levels. The cell line panels with varying levels of 
CK  and  Ki-67  expression  were  incubated  with  the 
targeted nanoparticles, and the fluorescence intensity 
was  measured.  Fluorescent  antibody  staining  and 
Western  blot  results  indicated  that  the  nanoparticle 
signals were closely correlated with expression levels, 
suggesting  a  chemoselective  Tz/TCO  cycloaddition 
reaction.  They  performed  NMR  profiling  of  the  in-
tracellular  proteins  using  the  diagnostic  magnetic 
resonance  (DMR),  which  was  developed  as  a  rapid 
point-of-care diagnostic technique for analyzing small 
cell populations [165]. Eight cells were labeled with 
MFNPs using the BOND scheme, and 1000 cells were 
analyzed  in  a  1  μL  sample  volume  of  a  hand-held 
NMR device (Figure 16B). The DMR profiling results 
correlated  with  the  expression  levels  of  the  target 
proteins, as measured by fluorescent antibody stain-
ing in larger samples (106 cells).  
 
Figure 15. (A) Schematic diagram showing the conjugation chemistry between an antibody and a nanoparticle. (B) Ap-
plication of BOND for one-step (direct) and two-step targeting of nanoparticles to cells. Note that the antibody and te-
trazine are shown to be present in multiple copies per nanoparticle. (C) Comparison of different nanoparticle targeting 
strategies. SKBR-3, HCT116, and A549 cells were labeled with different concentrations of MFNPs using the two-step 
BOND-2 or direct MFNP immuno-conjugates, and the fluorescence signal was measured using flow cytometry. MFNP 
immuno-conjugates were prepared either via maleimide/thiol or TCO/Tz (BOND-1) chemistries. The control samples were 
incubated with Tz-MFNP only. Reproduced with permission from ref. [163]. Theranostics 2012, 2(1) 
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Figure 16. (A) Semipermeabilization of intact cells allows for nanoparticle targeting to a variety of intracellular biomarkers. 
Indicators of cell growth, activation, and survival. (B) Profiling scant tumor cell populations for key biomarkers of cancer 
using DMR. Detection of eight biomarkers in eight different cell lines using MFNPs based on NMR signal (top). Magnetic 
measurements showed an excellent correlation with the marker expression levels determined independently using antibody 
staining (bottom). Reproduced with permission from ref. [164]. 
 
 
Hybridization method 
Richards-Kortum  et  al.  reported  a  novel  ap-
proach  to  conjugating  nanoparticles  and  aptamers 
[166].  The  aptamer  was  extended  to  provide  a  hy-
bridization  site  for  complementary  ONT-coated  na-
noparticles.  GNPs  (20  nm)  were  coated  with  thi-
ol-modified capture ONTs containing a hexa(ethylene 
glycol) spacer and a complementary sequence for the 
aptamer extension, and the extended anti-PSMA ap-
tamer was hybridized to capture ONT-coated GNPs 
by heating the solution at 70°C for 5 min, followed by 
incubation at room temperature for 30 min. The re-
sulting aptamer-GNPs showed targeted detection of 
LNCaP (PSMA+) cells via reflectance imaging. This 
conjugation strategy has several advantages. First, the 
negatively  charged  phosphate  groups  of  the  ONTs 
prevented  aggregation  of  the  nanoparticles  through 
electrostatic repulsion, leading to nanoparticle stabil-
ity, even in high-salt environments. Second, aptamers 
were easily conjugated to the surfaces of nanoparticles 
via complementary sequence hybridization with the 
capture ONTs, which preserved the aptamer integrity 
and  stability  during  bioconjugation.  A  PEG  spacer 
between  the  thiol  group  and  the  complementary 
capture sequence of capture ONT improved the hy-
bridization efficiency by minimizing steric hindrance 
between the gold surface and the hybridization site. 
Third, a small number of aptamers was needed for 
binding to the nanoparticles through the short cheap 
capture  ONTs,  unlike  thiolated  aptamers,  in  which 
significant concentrations of aptamers are necessary 
to coat and stabilize the nanoparticles. Finally, multi-
plexing capabilities can be obtained by incorporating 
other types of molecules (targeting, delivery, imaging, 
or therapeutic agents) into the nanoparticles.  
 Ellington et al. used this bioconjugation method 
to  conjugate  an  anti-EGFR  aptamer  onto  GNPs  to 
demonstrate the targeting specificity of a newly iden-
tified aptamer [127]. As described above, they coated 
GNPs  with  thiol-modified  capture  ONTs  that  hy-
bridized to an extended anti-EGFR aptamer to gener-
ate  anti-EGFR  aptamer-conjugated  GNPs.  Jon  et  al. 
utilized  the  hybridization  method  to  conjugate  an 
anti-PSMA-aptamer  to  iron  oxide  nanoparticle  sur-
faces  [123].  In  their  study,  CG-rich  duplexes  were 
constructed  at  the  ends  of  the  aptamers  to  achieve 
multiple  Dox-binding  on  the  nanoparticles.  They 
immobilized  amine-functionalized  capture  ONTs 
(5’NH2-A10-(TCG)7-3’) on the surfaces of the carbox-
yl-modified iron oxide nanoparticles. Magnet purifi-
cation  yielded  the  capture  ONT-coated  iron  oxide 
nanoparticles.  A  (CGA)7-extended  an-
ti-PSMA-aptamer  was  synthesized  by  in  vitro  tran-
scription,  and  the  aptamers  were  added  to  the 
ONT-coated  nanoparticles  to  produce 
Apt-hybr-TCL-SPIONs. Thermal gravimetric analysis 
(TGA)  indicated  that  PSMA  aptamers  (28,451  Da) 
hybridized to approximately 33% of the ONTs (9,708 
Da) conjugated to the nanoparticles.  Theranostics 2012, 2(1) 
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4. Surface engineering strategies for in vivo 
application 
In  general,  nanoparticles  tend  to  aggregate 
through  hydrophobic  interactions  or  attractive  van 
der Waals forces in an effort to minimize the surface 
energy.  In  the  blood  stream,  such  aggregates  can 
trigger opsonization, the process by which a particle 
becomes  covered  with  opsonin  proteins,  thereby 
making it more visible to the mononuclear phagocytic 
system (MPS), such as RES. The phagocytic mecha-
nisms render nanoparticles ineffective as theranostic 
devices  by  removing  them  from  the  bloodstream 
[167]. Therefore, evading uptake by RES and increas-
ing the blood circulation half-life are major challenges 
for  developing  theranostic  nanoparticles  in  clinical 
applications [168]. Several methods of camouflaging 
nanoparticles have been developed to yield ‘stealth’ 
nanoparticles, which are invisible to MPS. These ap-
proaches interfere with the binding of opsonin pro-
teins to the nanoparticle surfaces in support of a long 
circulation half-life, thereby increasing the chance that 
the nanoparticles can effectively target tumor sites. In 
order to impart stealth properties to the nanoparticles, 
one  of  the  most  promising  molecules  is  the 
FDA-approved PEG. Natural or synthetic polymers, 
small  organic  molecules,  and  core-shell  structures 
have also been utilized for nanoparticle surface coat-
ings. However, a high surface coverage can decrease 
binding to and uptake by target cancer cells. This sec-
tion describes the use of several coating molecules as 
shielding materials. The optimal surface densities of 
the coating materials and the targeted ligands will be 
discussed.  
Shielding strategy 
PEG is a biocompatible linear synthetic polymer 
that can be prepared in a range of sizes and with a 
variety  of  terminal  functional  groups.  PEG  is  com-
monly used to achieve stealth properties, due to its 
hydrophilicity, flexibility, and neutral charge in bio-
logical  fluids,  all  of  which  properties  help  disperse 
nanoparticles  and  increase  their  blood  circulation 
times [169,170]. Various methods have been used to 
attach  PEG  to  magnetic  nanoparticles,  including  in 
situ  coating  under  aqueous  conditions  [171], 
silane-grafted  PEG  coating  [172],  fabrication  of 
amine-functionalized 6-armed PEG derivatives [173], 
polymerization  at  nanoparticle  surfaces  [174],  or 
modification through sol-gel approaches [175]. Cova-
lent  attachment  of  one  end  of  a  heterobifunctional 
PEG to the magnetic nanoparticles and functionaliza-
tion of the other end with targeting ligands, imaging 
probes,  or  therapeutic  agents  have  been  described 
[176-178].  Jon  et  al.  developed  a  multifunctional 
poly(TMSMA-r-PEGMA-r-NAS)  capable  of  covalent 
anchoring onto iron oxide surfaces (silane functional-
ity), resisting protein absorption (PEG functionality), 
and  binding  to  functional  moieties  (carboxyl  func-
tionality)  [136].  Interestingly,  silane  functionalities 
were employed to cross-link polymer coating layers, 
formed by heat-mediated condensation of hydrolyzed 
silane groups (-Si(OH)3), to yield highly stable nano-
particles. This polymer facilitated fabrication of iron 
oxide  nanoparticles  and  demonstrated  their  in  vivo 
dual imaging (MR/optical) modalities in tumor xen-
ograft animal models. 
Copolymers containing PEG residues have been 
developed as a means of combining the properties of 
PEG  with  the  desired  properties  of  other  moieties. 
Chen and Shuai synthesized PEG-g-PEI copolymers 
that  condense  DNA  to  facilitate  gene  delivery  (PEI 
functionality) and display a stealth profile necessary 
for  in vivo applications  (PEG  functionality).  The  co-
polymers were used to construct PEG-g-PEI-SPIONs 
as MRI-visible gene carriers [60]. Zhang et al. prepared 
a  PEGylated  chitosan-branched  copolymer  to  coat 
iron  oxide  core  and  develop  brain  tumor  targeting 
magnetic/optical  nanoprobe.  Chitosan  is  a  hydro-
philic  and  biocompatible  natural  polymer  that  is 
popular as a theranostic nanocarrier material [179]. In 
a study by Zhang  et al., a PEG-grafted chitosan co-
polymer  was  prepared  using  a  Schiff  base  reaction 
between  PEG-aldehyde  and  amine-containing  de-
polymerized  chitosan,  and  nanoparticles  were  syn-
thesized by coprecipitation of ferrous and ferric chlo-
ride with ammonium hydroxide in the presence of the 
copolymer. The chitosan amine groups present on the 
surfaces  of  the  nanoparticles  were  coupled  to  the 
brain tumor targeting ligand, CTX. The presence of 
surface chitosan sterically stabilized the nanoparticles 
by preventing aggregation under physiological con-
ditions. Additionally, the positively charged chitosan 
cations  could  interact  with  the  negatively  charged 
brain  endothelium  via  electrostatic  interactions  to 
trigger adsorptive-mediated transport across the BBB. 
Jon  et  al.  developed  another  multifunctional  am-
phiphilic  copolymer,  poly(DMA-r-mPEGMA-r-MA), 
that  formed  an  efficient  coating  on  the  surfaces  of 
oleic acid-stabilized SPIONs [180]. Hydrophobic do-
decyl methacrylate (DMA) residues on the polymer 
bound  to  the  oleic  acid  tail  group  formed  a  shell 
around  the  SPIONs  via  hydrophobic  and  van  der 
Waals  interactions.  Hydrophilic  PEG  residues  im-
prove  the  water-dispersibility  of  nanoparticles  and 
prevent biofouling during in vivo molecular imaging. 
Finally, methacrylic acid (MA) residues can be used to 
introduce additional functionalities. Sonication of the Theranostics 2012, 2(1) 
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immiscible  phases  containing  oleic  acid-stabilized 
SPIONs in hexane or the amphiphilic polymer in wa-
ter created an oil-in-water emulsion. Evaporation of 
the hexane left a homogenous aqueous solution con-
taining amphiphilic polymer-coated SPIONs. The in 
vivo  diagnostic  capabilities  were  demonstrated  in  a 
Lewis Lung Carcinoma cell allograft animal model. In 
a similar approach, Hadjipanayis  et al. formed oleic 
acid-stabilized SPIONs using an amphiphilic triblock 
copolymer consisting of a polybutylacrylate segment 
(hydrophobic),  a  polyethylacrylate  segment  (hydro-
phobic),  a  polymethacrylic  acid  segment  (hydro-
philic),  and  a  hydrophobic  hydrocarbon  side  chain 
[52].  Strong  hydrophobic  interactions  between  the 
oleic acid and the hydrophobic residues of the poly-
mer  favored  spontaneous  encapsulation  of  the  SPI-
ONs.  The  surface-exposed  carboxyl  groups  of  the 
methacrylic acid segments covalently bound to EG-
FRvIIIAb to target glioblastoma, and PEG stabilized 
the dispersion under aqueous conditions.  
Polysaccharide dextrans are widely used as sur-
face shielding materials for in vivo applications. The 
biocompatibility and high affinity of dextrans toward 
iron  oxide  surfaces,  mediated  by  polar  interactions, 
including hydrogen bonds, provide excellent proper-
ties to SPIONs coated with dextrans, and several of 
the clinically approved SPION preparations are dex-
tran-coated [181-183]. Conventional dextran polymer 
coatings do, however, suffer some degree of detach-
ment from the nanoparticle surfaces due to the lability 
of  the  hydrogen  bonds.  Weissleder  et al. developed 
stable cross-linked iron oxide nanoparticles (CLIO) by 
cross-linking  the  dextran  polymer  using  epichloro-
hydrin  or  ammonia.  Ammonia  treatment  of  CLIOs 
introduced primary amine groups to the particle sur-
faces, which facilitated attachment of other functional 
moieties. The resulting nanoparticles were extensively 
evaluated in a variety of MRI and theranostic appli-
cations [71, 87, 184]. The CLIOs exhibited a long blood 
circulation time without inducing an acute toxic re-
sponse [185]; however, the persistence and stability, 
as  well  as  the  presence  of  trace  amounts  of  the 
epichlorohydrin  reactant,  were  problematic  in  the 
clinical  setting,  and  further  development  of  these 
agents has slowed [186].  
Atomic transfer radical polymerization (ATRP) 
is  another  common  method  for  coating  iron  oxide 
nanoparticles [187]. Li et al. used the ATRP method to 
synthesize  polystyrene-coated  iron  oxide  nanoparti-
cles  using  divinylbenzene  as  a  cross-linker  [188]. 
Several other polymers, including polyvinyl alcohol 
(PVA) [189], polyvinyl pyrrolidine (PVP) [190], and 
polyacrylic acid [191], were described as coating ma-
terials for  iron oxide nanoparticles. These polymers 
provided a steric barrier to prevent nanoparticle ag-
glomeration and enhance the blood circulation time. 
In addition, a variety of monomeric species, including 
bisphosphonates  [192],  dimercaptosuccinic  acid 
(DMSA)  [193],  and  alkoxysilanes  [194],  has  been 
evaluated as anchors to facilitate attachment of pol-
ymers  to the  nanoparticle surfaces. Cheon  et al. de-
veloped water-soluble iron oxide (WSIO) nanocrystals 
using DMSA as coating materials [195]. The DMSA 
formed a stable coating on the magnetic Fe3O4 nano-
crystals  through  carboxylic  chelating  bonds,  then 
further  stabilized  the  shells  through  intermolecular 
disulfide  cross-linkages.  The  remaining  free  DMSA 
thiol groups were linked to a breast cancer-targeting 
molecule,  Herceptin.  The  WSIO-Herceptin  probes 
specifically targeted breast cancer cells to provide a 
targeted  MRI  contrast  agent,  as  revealed  by 
T2-weighted MRI. Cheon et al. also developed a hy-
brid  nanoparticle  probe  for  PET/MR  imaging  con-
sisting of albumin-stabilized iron oxide nanoparticles 
[196].  Serum  albumins  were  linked  to  oleic  ac-
id-coated  manganese-doped  magnetic  engineered 
iron  oxide  (MnMEIO)  nanoparticles  via  ligand  ex-
change,  and  the  surfaces  of  the  nanoparticles  were 
further  stabilized  by  EDC/NHS-mediated 
cross-linking between the amine and carboxyl groups 
of the serum albumin. The resultant MnMEIO nano-
particles showed high colloidal stability over a wide 
range of pH and at high salt concentrations. The tyro-
sine residues in the serum albumin could be directly 
conjugated to 124I to introduce radioactive properties. 
This nanoparticle platform was also used to develop 
all-in-one  target  cell-specific  magnetic  nanoparticles 
for simultaneous molecular imaging and siRNA de-
livery  [197].  To  target  αvβ3  integrin-positive  cancer 
cells  and  to  inhibit  specific  protein  expression, 
SH-PEG-RGD and SH-siRNA-Cy5, respectively, were 
conjugated to MnMEIO via an SPDP cross-linker. In 
vitro  evaluation  of  MRI  and  gene  suppression 
demonstrated  that  these  multimodal  nanoparticle 
systems  selectively  silenced  genes,  confirming  their 
theranostic behavior. 
Liposomes and micellar dispersions provide an-
other shielding strategy. Spherical assembles of am-
phiphilic molecules can be used to coat magnetic na-
noparticles by incorporating the nanoparticles within 
hydrophilic  or  hydrophobic  cores  to  enhance  blood 
circulation  time.  The  amphiphilic  substructures  can 
encapsulate  additional  therapeutic  agents  or  func-
tional  molecules  within  the  core  to  easily  achieve 
multifunctional nanoparticles. Lesieur et al. developed 
magnetic-fluid-loaded  liposomes  (MFLs)  by  encap-
sulating  maghemite  (γ-Fe2O3)  nanocrystals  in  the 
unilamellar  vesicles  of  (DSPE)-mPEG2000  and  egg Theranostics 2012, 2(1) 
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phosphatidylcholine  [198].  MFLs  with  a  hydrody-
namic size of 195 ± 33 nm were prepared by film hy-
dration followed by extrusion. The particles were sta-
ble without the need for ferrofluid flocculation under 
physiological conditions.  In vivo tests in mice using 
MR angiography demonstrated that the presence of 
MFLs enhanced the image contrast significantly, and 
the particles persisted in the blood 24 h after injection, 
possibly  due  to  the  stealth  properties  conveyed  by 
PEGylation of the MFLs. Huh and Haam developed 
multifunctional  magneto-polymeric  nanohybrids 
(MNPNs) using polymeric micelles, and they evalu-
ated the in vivo uses of the particles for simultaneous 
diagnosis  and  therapy  [199].  Water  solubility  was 
achieved  by  embedding  the  hydrophobic  magnetic 
nanocrystals  and  Dox  within  amphiphilic 
poly(ethylene  glycol)-block-poly(D,L-lactic-co- 
glycolic  acid)  (PEG-PLGA)  using  nanoemulsion 
methods,  and  Herceptin  was  conjugated  to  the  ter-
minal  PEG-PLGA  carboxyl  groups  for  selective  tar-
geting.  Manganese  ferrite  (MnFe2O4)  and  Dox  were 
present in the MNPNs at 41.7 wt% and 3.3 wt%, re-
spectively.  In  vivo  MRI  and  therapeutic  tests  in  a 
mouse  model  bearing  NIH3T6.7  cells  demonstrated 
that  the  Herceptin-conjugated  multifunctional  poly-
meric micelles were site-specifically delivered to the 
tumor  tissues  that  overexpressed  HER2/neu  recep-
tors. The particles retarded the rapid growth of the 
tumors. Gao et al. used polymeric micelles to prepare 
αvβ3  integrin  targeting  theranostic  nanoparticles 
[200].  The  amphiphilic  block  copolymers  of  malei-
mide-terminated  poly(ethylene  gly-
col)-block-poly(D,L-lactide)  (MAL-PEG-PLA)  and 
methoxy-terminated  poly(ethylene  gly-
col)-block-poly(D,L-lactide)  (MPEG-PLA)  were  used 
to form micelles. Oleic acid- and oleylamine-stabilized 
SPIONs and  Dox were encapsulated into polymeric 
micelles via a solvent evaporation method, and thi-
ol-containing cRGD was attached to the surfaces of 
the  micelles.  In  vitro  MRI  and  cytotoxicity  studies 
confirmed the ultrasensitivity, enhanced MRI contrast 
properties,  and  αvβ3  integrin-specific  therapeutic 
response  to  the  multifunctional  nanoplatform.  The 
presence  of  ionizable  ammonium  groups  on  Dox 
(PKa=7) suggested that the drug release rate should be 
pH-dependent.  
In addition to organic coatings, core-shell struc-
tures,  such  as  biocompatible  silica-  or  gold-covered 
magnetic nanoparticles, have provided an attractive 
approach  to  developing  stealth  nanoparticles.  Silica 
shells serve as protective stable nanoparticle coatings 
under aqueous conditions. The ability to encapsulate 
functional molecules within the nanoparticle matrix is 
a unique feature of these nanostructures. Hyeon and 
Moon  developed  Fe3O4  nanocrystal-embedded, 
core-shell mesoporous silica nanoparticles, and they 
demonstrated  their  multifunctional  application  to 
simultaneous MR/optical imaging and drug delivery 
[201]. This study suggested a precise method for con-
trolling the size of the silica nanoparticles smaller than 
100  nm.  The  surfactant  cetyltrimethylammonium 
bromide (CTAB) provided an organic template for the 
formation of a mesoporous silica shell and stabilized 
the  hydrophobic  Fe3O4  nanocrystals  in  an  aqueous 
solution.  The  sol-gel  process  occurred  through  the 
template by using tetraethylorthosilicate (TEOS) and 
rhodamine  B  isothiocyanate  (RITC)-labeled  ami-
nopropyltriethoxysilane (APS), and generated amine 
groups containing silica shell, to which PEG was co-
valently  conjugated  via  succinimidyl  end  group  to 
render  further  biocompatibility.  Dox  molecules 
loaded onto the as-synthesized Fe3O4@mSiO2(R)-PEG 
NPs to convey therapeutic properties. The core-shell 
structure exhibited magnetic and fluorescent proper-
ties,  as  well  as  a  therapeutic  index,  suggesting  the 
utility of the nanostructure in biomedical theranostic 
applications. On the other hand, gold provides several 
advantages as a coating material due to its inertness 
and  its  unique  ability  to  absorb  near-IR  radiation. 
Hyeon  and  Cho  et  al.  described  magnetic  gold 
nanoshells (Mag-GNS) consisting of gold nanoshells 
encapsulating magnetic Fe3O4 nanoparticles as a nov-
el nanomedical platform for simultaneous diagnostic 
imaging and thermal therapy [202]. Monodisperse 7 
nm  Fe3O4  nanoparticles  stabilized  with 
2-bromo-2-methylpropionic acid (BMPA) were cova-
lently  attached  to  amino-modified  silica  spheres 
through  a  direct  nucleophilic  substitution  reaction 
between  the  bromo  groups  and  the  amino  groups. 
Gold  seed  nanoparticles  were  then  attached  to  the 
residual amino groups of the silica spheres. Finally, a 
complete 15 nm thick gold shell embedded with Fe3O4 
nanoparticles  formed  around  the  silica  spheres  to 
generate  Mag-GNS.  To  target  breast  cancer,  an  an-
ti-HER2/neu antibody was conjugated onto the sur-
faces  of  the  Mag-GNS.  SKBR3  breast  cancer  cells 
treated  with  Mag-GNS  could  be  detected  using  a 
clinical MRI system, followed by selective destruction 
by near-IR radiation. 
A new class of non-biofouling zwitterionic ma-
terials was recently developed [203]. The low fouling 
properties  with  respect  to  blood  serum  or  plasma 
were  attributed  to  strong  interactions  between  the 
zwitterions  and  the  neighboring  water  molecules, 
thereby offering good colloidal stability. The zwitter-
ionic  state  was  macroscopically  neutral  with  a  net 
zero  charge  that  provided  a  non-fouling  surface 
[204-206]. In vivo tests of the zwitterion-coated QDs Theranostics 2012, 2(1) 
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demonstrated that the surfaces were protein-resistant, 
which made it possible for the QDs to remain small 
relative to the PEG-decorated particles [207,208]. Jiang 
et  al.  developed  poly(carboxybetaine  acrylamide) 
(polyCBAA)-functionalized surfaces that were used to 
stabilize gold nanoparticles using the ATRP method 
[209].  This  surface  platform  was  highly  resistant  to 
nonspecific  protein  adsorption,  and  it  presented 
abundant  carboxyl  groups  for  biomolecule  immobi-
lization.  However,  ATRP  reactions  require  sur-
face-grafted  initiators  and  oxygen-free  conditions, 
which limit their practical application. This problem 
was  addressed  by  another  strategy,  the 
‘graft-to-surface’  method  [210],  in  which  a  zwitteri-
onic  poly(carboxybetaine  methacrylate)  (pCBMA) 
polymer  was  grafted  onto  the  surface  via  two 
3,4-dihydroxyphenyl-L-alanine  (DOPA)  adhesive 
moieties, and iron oxide nanoparticles were fabricated 
from  the  as-synthesized  pCBMA-DOPA2. 
Amine-containing cRGD peptides were immobilized 
onto the nanoparticles via the EDC/NHS chemistry. 
pCBMA-DOPA2-decorated  magnetic  nanoparticles 
exhibited a lower macrophage uptake than the dex-
tran-coated  magnetic  nanoparticles.  Uptake  by  hu-
man  umbilical  vein  endothelial  cells  (HUVEC)  was 
considerably higher due to cRGD-mediated targeting, 
as demonstrated by MRI studies.  
Optimal density of the non-biofouling moieties 
and targeting ligands  
Non-biofouling  moieties,  present  as  shielding 
materials, not only provide a steric barrier to prevent 
nonspecific  protein  absorption,  they  can  tailor  the 
surface  properties  of  the  nanoparticles  to  avoid 
recognition  by  the  RES.  The  successful  in vivo  per-
formance of a nanoparticle system relies critically on 
the non-biofouling properties, the molecular weight, 
the surface structural conformation, and the surface 
coverage  ratio  [211,212].  The  surface  density  and 
conformation  are  important  features  for  improving 
the  stealth  and  targeting  efficiency.  To  this  end, 
PEG-linked  liposomal  nanoparticle  surfaces  have 
been engineered. As shown in Figure 17, individual 
PEG chains on a liposomal surface exhibited a Flory 
dimension, Rf, which represents the volume occupied 
by each flexible PEG molecule [213].  
 
 
 
Figure 17. Representations of different PEG conformations, formed through their incorporation onto surfaces at different 
densities. (A) Low surface coverage levels of PEG lead to the “mushroom” configuration (D>Rf). (B) High surface coverage 
levels restrict the mobility of the PEG chains and lead to the “brush” configuration (D<Rf). Reproduced with permission 
from ref. [213] and [216]. 
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A high surface coverage and a high concentra-
tion of the PEG-lipids within a liposomal formulation 
decrease the distance, D, between each PEG molecule 
on the nanoparticle surface. If D>Rf, the PEG chains 
self-assemble  into  a  random-coil  like  ‘mushroom’ 
configuration. On the other hand, if D<Rf, the lateral 
pressure between the overcrowded PEG extends the 
PEG  chains  to  a  semi-linear  ‘brush’  configuration 
[214]. In general, the brush configuration of surface 
PEGs conveys greater protein repulsion and enhanced 
nanoparticle  lifetime  in  the  blood  stream  [215-217]. 
This surface configuration can also decrease the mo-
bility  of  the  PEG  chains,  thereby  diminishing  the 
stealth  functionalities  of  the  PEG  layer  [218],  and 
hinder binding between the targeting ligands of the 
nanoparticles and the target cancer cells [213]. There-
fore, the surface coverage of the nanoparticle must be 
optimized during the design of any theranostic sys-
tem.  
Despite the critical role of the targeting ligand 
density on the nanoparticle surfaces, few studies have 
reported maximization of a nanoparticle system tar-
geting efficacy. Higher concentrations of the targeting 
ligands  on  the  nanoparticles  often  increase  cellular 
uptake [219,220]. Targeting ligands must be present 
on  the  nanoparticle  surfaces  at  concentrations  that 
exceed  a  minimum  threshold  for  binding  [221]. 
However, some studies also demonstrated that high 
ligand densities do not improve binding to the target 
cancer cells and can even promote nonspecific inter-
actions  with  endothelial  and  other  non-cancerous 
cells, which increases immunogenicity, thereby caus-
ing opsonization-mediated clearance of the nanopar-
ticles [222]. Gao et al. prepared 0%, 5%, or 16% RGD 
ligand-immobilized Dox-loaded polymeric micelles to 
investigate  their  in  vitro  targeting  and  therapeutic 
properties [200]. The 16% RGD ligand-bearing nano-
particles  displayed  the  highest  cellular  uptake  and 
cytotoxicity  in  αvβ3  integrin-overexpressing  SLK 
cells. Berkland et al. modulated the reactive sites on 
the nanoparticle surfaces for peptide conjugation by 
controlling  the  mixture  ratio  of  the  two  surfactants 
during nanoparticle fabrication [223]. They prepared 
PLGA  nanoparticles  with  several  ratios  of  the  car-
boxyl and hydroxyl groups in the Pluronic® surfactant 
(100:0 75:25, 50:50, 25:75, and 0:100 (v/v)), and cLABL 
peptides were conjugated to the surfaces to achieve 
intercellular  cell  adhesion  molecule-1  (ICAM-1)  tar-
geting. Incubation of the cLABL-PLGA nanoparticles 
with the target A549 cancer cells revealed a maximum 
uptake  for  surfactant  ratios  of  50:50  or  25:75.  Inter-
estingly, the minimum uptake occurred for the sur-
factant ratios of 100:0 and 75:25. The enhanced recep-
tor  binding  at  moderate  ligand  densities  may  have 
been  due  to  receptor  behavior  during  the  binding 
process. ICAM-1 mobility on the cell surface leads to 
clustering  during  ligand  binding  [224],  and  a  high 
density of the targeting ligands can disturb the clus-
tering.  This  result  suggests  that  the  ligand  spacing 
should be considered during surface engineering of 
targeted nanoparticle systems. Recently, Ashley et al. 
developed  targeted  silica  nanoporous  parti-
cle-supported lipid bilayers that provided enhanced 
surface fluidity, which recruited multiple peptides to 
the target cancer cells to promote multivalent effects 
[6]. The unique long-range fluidity of the nanoparticle 
surface promoted a high affinity between the target-
ing peptides on the nanoparticles and the target can-
cer cells at low peptide densities (6 peptides per par-
ticle).  This  specific  targeting  is  crucial  for  reducing 
nonspecific interactions and enhancing specific affin-
ity, which maximize the selective delivery of a cargo.  
It  has  become  increasingly  clear  that  the  tu-
mor-targeting  properties  of  the  nanoparticles  opti-
mized in vitro are not predictive of the in vivo perfor-
mance. Farokhzad and Langer identified  maximally 
targeted  and  maximally  stealth  surface  engineering 
conditions for in vitro and in vivo performance using 
PSMA  targeted  aptamer-conjugated  Dtxl-loaded 
self-assembled  nanoparticles  [225].  Nanoparticles 
were  prepared  with  different  compositions  of  the 
self-assembled diblock copolymers and aptamers, and 
the optimal aptamer density on the nanoparticle sur-
face was initially determined in vitro. Increasing the 
ligand density to 5% significantly increased the na-
noparticle  uptake  by  the  target  cells  (LNCaP), 
whereas further increase in aptamer density modestly 
increased  the  nanoparticle  uptake.  These  results  in-
dicated  that  the  optimum  ligand  density  for 
PSMA-specific  endocytosis  in vitro  was  10–80  nmol 
aptamer  per  μmol  nanoparticle.  LNCaP  xenograft 
mouse models injected with the targeted nanoparti-
cles showed that increasing the aptamer density from 
0% to 5% significantly increased nanoparticle reten-
tion  in  tumors,  but  the  retention  decreased  for  ap-
tamer densities beyond 10%. The authors suggested 
that higher aptamer densities may have reduced the 
nanoparticle  stealth  properties,  resulting  in  rapid 
clearance  by  the  liver.  Gabizon  et al.  optimized  the 
ligand density in the Her2-targeted PEGylated lipo-
somal Dox system (HT-PLD) in vivo for ligand ratios 
of 7.5, 15, or 30 per liposome [226]. The best safety 
margin and in vivo performance resulted from a lig-
and density of 15 ligands per liposome in the HT-PLD 
formulation.  A  30  ligand  ratio  accelerated  plasma 
clearance in the tumor-bearing mice, and the 7.5 lig-
and ratio reduced cytotoxicity after in vivo passage.  
The role of nanoparticle geometry in tumor tar-Theranostics 2012, 2(1) 
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geting has received relatively little attention, although 
it is important for determining the binding affinity for 
a target cell. Sailor et al. systemically optimized in vivo 
tumor  targeting  by  varying  the  nanomaterial  shape 
(elongated  versus  spherical),  targeting  ligand  type 
(cell surface targeting versus extracellular matrix tar-
geting),  ligand  surface  coverage,  and  attachment 
chemistry (Figure 18) [227]. They prepared two types 
of tumor-targeting peptides (F3 or CREKA) and con-
jugated the peptides to magnetic nanoworms (NWs) 
or magnetic nanospheres (NSs) at varying numbers of 
targeting peptides and for varying PEG lengths. In-
travenous injection of the magnetic nanostructures in 
the tumor xenograft mice models revealed that the in 
vivo tumor-targeting properties of the NWs were su-
perior to those of the NSs due to multivalent interac-
tions between the elongated NWs and the receptors 
on  the  tumor  cell  surfaces.  The  smaller  neutral 
CREKA targeting moiety was more effective than the 
larger  positively  charged  F3  targeting  moiety,  pre-
sumably because multiple copies of the highly cati-
onic F3 caused a large increase in the surface charge 
on  the  particles,  which  facilitated  clearance  by  the 
MPS-related  organs.  The  most  effective  number  of 
CREKA peptides was 60 per NW. Above 60 peptides 
per NW, the blood circulation time decreased. For a 
given  number  of  peptides  bound  to  the  NWs,  the 
presence of a PEG linker facilitated peptide targeting 
by reducing conformational restriction as well as in-
creasing the residence time of the nanostructures in 
the blood stream. The short SMCC linker restricted 
the  targeting  peptide  conformation.  These  results 
suggest some design guidelines for the development 
of targeted multifunctional nanoparticle systems for 
cancer imaging and therapy. 
 
 
 
Figure 18. Three parameters were varied to optimize in vivo tumor targeting: the shape of the nanoparticle, the type of the 
targeting ligand, and the nature of the molecular linker. Two types of surface linkers were used to attach the targeting groups 
to the magnetic NWs or NSs. A short hydrocarbon places the targeting peptide (either F3 or CREKA, green lines) in close 
proximity to the dextran-coated nanostructure. A 5 kDa PEG linker places the targeting peptide further from the surface. 
The number of targeting groups per NW was varied to maximize the in vivo circulation time and optimize the in vivo tu-
mor-targeting efficiency. These linker chemistries were tested on magnetic NSs. The NWs consisted of several NS cores 
linked together in a chain. Reproduced with permission from ref. [227]. 
 
 
5. Conclusions and perspectives 
Considerable effort has been  made toward the 
research  and  development  of  multifunctional  nano-
particle  systems  for  cancer  targeted  imaging  and 
therapy. Among the nanoparticle platforms, magnetic 
nanoparticle-based theranostic systems show partic-
ular promise. The intrinsic magnetic properties lend 
themselves  to  diagnostic  MRI  applications,  and  the 
surfaces  may  be  easily  modified  using  a  variety  of 
targeting moieties, such as antibodies, peptides, small 
molecules, aptamers, or therapeutic agents through a Theranostics 2012, 2(1) 
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number of conjugation strategies. Furthermore, mag-
netic nanoparticles unlike other inorganic nanoparti-
cles such as gold- and carbon-based ones can be de-
graded to Fe ions in the body particularly in the acidic 
compartments of cells (e.g. lysosomes), alleviating the 
potential toxicity of long-term residence of nanopar-
ticles. Therefore, magnetic nanoparticle formulations 
are  considered  valuable  tool  for  disease  diagnosis 
with anatomical details at an early stage, delivery of 
therapeutic agents to the target tumor sites, real-time 
monitoring  of  therapeutic  responses,  thereby  cur-
rently attracting increasing interest for clinical utility. 
For the preparation of nanoparticles in potential clin-
ical uses, it is critical to be aware of the design pa-
rameters discussed in this review. Better characteri-
zation  methodologies  are  also  needed,  including 
pharmacokinetics and long-term toxicity studies. The 
costs required to integrate multiple components is an 
additional  consideration  for  commercial  viability. 
Although all such considerations are to be resolved in 
the near future, one should consider the regulatory 
hurdles  encountered  during  clinical  trials.  The  re-
quired regulatory processes become more complexed 
with the multifunctionalities of the nanoparticles be-
cause they are consisted of multiple additional com-
ponents and also claim multiple indications with sin-
gle nanoparticle. Nontheless, there is high probability 
that  cancer-specific  nanoprobes  arming  with  thera-
peutic capabilities are to be used in clinic in the near 
future because they are able to meet unmet medical 
needs  for  effective  cancer  treatments  with  minimal 
adverse effects.  
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